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Aging represents a highly heterogeneous process with highly variable clinical outcomes. 
Differential expression of risk and resilience factors may provide explanations for this variability. 
Gaining a better understanding of resilience in aging is critical as it will allow for improved 
individualized outcome prediction, as well as providing insight for targeted interventions that may 
improve the process of aging. Currently, the prevailing models of neurocognitive resilience are 
cognitive reserve and brain reserve. The theory of cognitive reserve suggests that those with greater 
cognitive reserve may better cope with loss of brain integrity through presence of more adaptable 
and efficient neural systems. Most studies utilize education level to assess cognitive reserve; 
however, many proxy measures are subjective and susceptible to hindsight bias. The concept of 
brain reserve overlaps with that of cognitive reserve but focuses instead on the biological 
characteristics that allow the brain to be resilient to the effects of aging and pathological insults. It 
is generally thought that with sufficient brain substrate (e.g., larger grey matter volumes, greater 
synaptic density, more elaborate network complexity), the brain is more capable of preserving 
normal functioning and maintaining homeostasis despite the presence of factors of 
neurodegeneration or trauma. Overall, the main goals of this dissertation are to demonstrate the 
impact of cognitive and brain reserve on neuropsychological outcomes and brain activation 
patterns (Aim 1, Chapters 2 and 3), to utilize machine learning brain age prediction as a novel 
proxy of brain reserve (Aim 2, Chapter 4), and to utilize brain age prediction in several 
 v 
neuropsychiatric disorders to predict outcome or gain a better understanding on the disease process 
(Aim 3, Chapters 5, 6, 7). 
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1.0 General Introduction 
This chapter provides a general introduction regarding brain aging, resilience, and age-
related neuropsychiatric disorders. Here we will discuss the major biological processes involved 
in aging, the homeostatic process of maintaining normal aging over time, factors that may provide 
resilience in healthy aging and disease, and examples of age-related neuropsychiatric disorders. 
 
This chapter contains excerpts from the following review papers that have been published 
previously:  
• Mizuno, A., Ly, M., Aizenstein, H.J. A Homeostatic Breakdown Model of Subjective 
Cognitive Decline (2018) Brain Sciences. 8(12), 228.  
• Ly, M., Andreescu, C. Advances and Barriers for Clinical Neuroimaging in Late-Life 
Mood and Anxiety Disorders (2018) Current Psychiatry Reports. 20(1): 7. 
 
My contributions to both of these review papers were literature review, interpretation of 





Due to the combination of declining fertility rates, improved survival, and increasing 
lifespan, the global population of older adults (60+) is rapidly increasing. It is estimated that by 
2030, older adults will outnumber children aged 10 years and younger. Notably, by 2050, older 
adults will outnumber individuals below 24 years of age. As such, it is becoming of increasing 
importance to mitigate the widespread impact of age-related functional decline and disease.  
1.1.1 Definitions and examples of aging 
Aging can be broadly defined as a progressive, time-dependent process in which living 
organisms accumulate cellular and molecular damage. The cumulative burden of cellular damage 
to tissues and organs may lead to compromised physiological integrity, functional impairment, and 
increased morbidity and mortality. Common examples of physiological changes that occur with 
aging include decreased cardiac output, accumulation of atherosclerotic plaque, impaired 
pulmonic gas exchange, decreased vital capacity, decreased creatinine clearance, reduction in lean 
body mass, and degenerative changes in many joints (Boss 1981). Critically, increased age has 
been demonstrated to be the primary risk factor for a wide range of diseases and disorders, such as 
but not limited to cancer, type 2 diabetes mellitus, cardiovascular diseases, coronary artery disease, 
and neurodegenerative diseases.  
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1.1.2 Theories of aging 
The prevailing theories of aging are generally split on the basis of the source of the 
accumulated cellular and molecular damage: extrinsic (stochastic) or intrinsic (developmental-
genetic) (Aalami 2003 et al.). The stochastic theories of aging primarily ascribe damage to extrinsic 
sources, such as environmental exposure to free radicals and radiation, lifestyle factors (e.g. 
excessive sunbathing, cigarette smoking), and long-term accumulation of errors (e.g. faulty 
splicing). On the other hand, developmental-genetic theories assert that cellular and molecular 
damage occur as part of a “planned obsolescence”—that physiological deterioration occurs as part 
of an intrinsic, pre-programmed, genetic process (Finch et al. 2001). It is important to note that 
these theories do not necessarily represent contradictory views, as it is likely that aging 
encompasses aspects from both extrinsic and intrinsic sources of cellular and molecular damage.  
1.1.3 The cellular and molecular hallmarks of aging 
In a seminal review paper, Lopez-Otin proposed nine potential cellular and molecular 
hallmarks of aging that were selected with the following criteria: 1) the phenomena must be 
observable during the process of non-pathological aging, 2) exacerbation of the mechanism must 
result in an accelerated aging, and 3) reversal of the process must slow down the process of aging 
(Lopez-Otin 2013). The hallmarks of aging include genomic instability, telomere attrition, 
epigenetic alterations, loss of proteostasis (protein homeostasis), deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular 
communication (Table 1). 
 4 
Table 1: The hallmarks of aging.   
Hallmark Putative biomarker  
Genomic Instability Micronucleus assay • Examples: premature aging 
diseases (Werner syndrome, 
Bloom syndrome) 
• Exposure to exogenous 
physical, chemical, 
biological agents, UV/IR 
radiation 
• DNA replication errors, 
spontaneous hydrolytic 
reactions, reactive oxygen 
species 
• Point mutations, 
translocations, 
chromosomal gains and 
losses, telomere shortening, 




Telomere length • Examples: Telomerase 
deficiency associated with 
premature pulmonary 
fibrosis, dyskeratosis 
congenita, aplastic anemia 
• Most mammalian somatic 
cells lack telomerase 
Epigenetic Alterations DNA methylation 
clocks 
• Histone modifications, 
DNA methylation, 
chromatin remodeling 
Loss of Proteostasis 
 




mediated protein folding 











Sirtuin 1 • Converse example: dietary 
restriction increases lifespan 
• Anabolic signaling 
accelerates aging (GH, IGF-





Factor 15, Apelin 
• Examples: cachexia, 
sarcopenia 
• Respiratory chain efficacy 
diminishes, leading to 
electron leakage, decreased 
ATP, increased ROS 
Cellular Senescence 
 
P16INK4A • Examples: frailty, disability 
• Accumulation of senescent 
cells increases with age 
• Senescence may be an 
adaptive response to 
minimize proliferation of 
damaged tissue; however, 
replacement in aged 
systems are limited 




• Example: decreased 
hematopoiesis leads to 
increased anemia and 
myeloid malignancies 
• Deficient proliferation of 










• Peri- and extracellular 
environment altered 
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1.2 Brain Aging  
While age-related physiological changes may occur in all organ systems, the focus of this 
dissertation will be on the process of aging in the brain. The processes occurring in brain aging are 
consistent with the overall hallmarks of aging. Parallel cellular and molecular mechanisms include 
altered calcium ion signaling, decreased synaptogenesis and neurite outgrowth, excessive 
demyelination, inappropriate microglial activation, astrocytic hypertrophy, and decreased neural 
activity (Blalock 2003).  
1.2.1 Structural brain aging  
Aging of the brain is characterized by consistent, non-linear patterns of structural 
alterations that are detectable with conventional and advanced neuroimaging. In general, structural 
changes in the aging brain can be detected in-vivo with computed tomography (CT) and magnetic 
resonance imaging (MRI). However, MRI is more favored and more commonly utilized for the 
study of structure and function of the brain due to its low risk profile (non-ionizing, non-invasive), 
repeatability, high resolution, and broad range of available modalities for the study of different 
tissue types. Overall, structural changes that occur in the process of normal aging generally include 
decreased global cerebral volume with regional differences, decreased grey and white matter 
density, increased ventricular or cerebrospinal fluid volume, increased white matter hyperintensity 
burden, and decreased white matter tract integrity (Lockhart and DeCarli 2014). 
Decreases in grey matter density are generally thought to represent neuronal degeneration 
and synaptic density reduction (Lockhart and DeCarli 2014), while decreases in white matter 
density may represent a change in myelinated fiber size, demyelination, expansion in perivascular 
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spaces (Virchow-Robin spaces), or gliosis (Meier-Ruge 1992). Alterations in grey matter and 
white matter density occur across the lifespan but with differing patterns. Grey matter volumes 
start decreasing somewhat linearly in adolescence or early adulthood and continue into late-life 
(Fotenos 2005). White matter volume increases until approximately age 40 and then declines with 
an accelerated quadratic rate (Fotenos 2005). Overall, the acceleration of whole brain volume 
reduction begins to be evident at approximately age 30 (Fotenos 2005).  
Age-related decreases in grey matter volume have been demonstrated to affect certain 
regions more than others. This seeming predilection has been traditionally ascribed to regional 
vulnerability to age-related changes or pathologies (Fjell 2014). Alternatively, it has also been 
suggested that the regions developed later during development (which also developed later in the 
context of mammalian nervous system evolution) are more susceptible to age-related changes 
(Fjell 2014). In general, grey matter volumes tend to decrease most in the frontal lobe followed by 
the temporal lobe, while volumes in the occipital and parietal lobe are largely preserved in the 
absence of other neurodegenerative causes (DeCarli 2005). Furthermore, rates of atrophy in the 
frontal lobe demonstrate a two-phase rate of change across the lifespan, with accelerated atrophy 
between age 20 and 40, a period of lower atrophy from 40-60, followed by a period of accelerated 
atrophy after age 60 (Pfefferbaum 2013). In general, the regions that are most commonly affected 
by decreased grey matter volume are the caudate nucleus, cerebellum, hippocampus, prefrontal 
cortex, orbitofrontal cortex, inferior temporal cortex, inferior parietal cortex, and the entorhinal 
cortex (Raz 2005). 
In comparison to the current literature on grey matter changes in aging, white matter 
changes are somewhat understudied in comparison. Similar to the pattern of grey matter atrophy, 
decreases in white matter integrity tend to follow the “last-in-first-out" hypothesis, in which 
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regions that myelinate later during development exhibit greater vulnerability to age-related 
changes or pathologies (Bennett and Madden 2014). The most prominent regions of age-related 
reduction of white matter integrity, as reflected by decreased fractional anisotropy (FA) and 
increased mean diffusivity (MD) on diffusion tensor imaging (DTI), are the genu of the corpus 
callosum, fornix, and the external capsule (Bennett and Madden 2014).  
Reductions in white matter integrity can be explained by the presence of white matter 
atrophy and the formation of white matter hyperintensities (Vernooij 2008). White matter 
hyperintensities (WMH) are lesions that appear bright on fluid attenuated inversion recovery 
(FLAIR) images in deep or periventricular white matter regions. WMHs are commonly detected 
in asymptomatic older adults, occurring in approximately 10% - 20% of 60-year olds to 
approximately 90% - 100% of 90-year olds (Merino 2019). WMHs represent a manifestation of 
small vessel disease and result from chronic, subclinical levels of ischemia. Risk factors for WMH 
include diabetes, hypercholesterolemia, smoking, carotid artery disease, atrial fibrillation, and 
heart failure. 
1.2.2 Cognitive brain aging 
As part of the process of brain aging, healthy older adults demonstrate decline in some 
cognitive domains while maintaining normal performance in other domains. This pattern is highly 
consistent with the pattern of structural changes in aging. As compared with younger adults, older 
adults most commonly demonstrate decline in the following aspects of cognition: attention, 
executive functioning, non-verbal/visuospatial processing, processing speed, working memory, 
and episodic memory (Dumas 2015, Lockhart and DeCarli 2014). However, older adults are able 
to maintain their performance or even demonstrate improvement in cognitive abilities that rely on 
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wisdom or general knowledge (e.g. fluency, verbal ability). Cognitive ability is commonly 
assessed through neuropsychological testing, and a sample comprehensive neuropsychological 
battery can be seen in Chapter 2.  
1.3 Resilience 
1.3.1 Heterogeneity of brain aging 
Despite the fact that the major biological processes and structural changes associated brain 
aging follow consistent patterns, aging represents a highly heterogeneous process with a wide 
range of intra-individual variability. By nature of the definition of aging, there is a large variety of 
potential sources of cellular and molecular damage that different individuals accumulate over the 
period of their lifetime. The genetic diversity of the human species also provides differential 
patterns of risk and resilience in different populations. In some cases, certain individuals are able 
to retain their cognitive ability and brain volume despite advancing into their eighth decade 
(Wilson 1999, DeCarli 2005b).  
The wide range of heterogeneity in aging leads us to the necessary discussion of 
nomenclature in aging (i.e. the differentiation between healthy and normal aging). Normal brain 
aging is characterized by typical patterns of age-related decline in structure and function in the 
absence of clinically significant impairment (or neurodegeneration attributable to other causes). 
On the other hand, healthy brain aging represents the more uncommon pathway characterized by 
preserved structure and function in light of advanced age (Lockhart and DeCarli 2014). It is 
presumed that the individuals who experience healthy brain aging have certain characteristics that 
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render them resilience to the ravages of time. In the following section, we will discuss the 
prevailing theories of cognitive and brain reserve that contribute to resilience in the context of 
brain aging.  
1.3.2 Reserve 
Cognitive reserve represents the ability of an individual to resist functional impairment in 
light of brain injury (Stern 2009, Stern 2012, Stern 2018). This theory suggests that those with 
higher cognitive reserve may better cope with brain damage through presence of higher premorbid 
cognitive abilities and more efficient recruitment of compensatory processes. Traditionally, these 
compensatory processes have been elicited through task-based functional MRI (fMRI), as 
discussed below.  
Cognitive reserve is commonly estimated by proxy measures, such as levels of education, 
occupational attainment, occupational complexity, lifetime socioeconomic status, bilingualism, or 
lifetime scholarly leisure activities. These proxies have been demonstrated to be associated with 
higher cognitive performance and/or delayed onset to Alzheimer’s disease as compared with age-
matched controls (Stern 1994, Scarmeas 2001, Amieva 2014, Wang 2017, Vermuri 2011, Soldan 
2015).  
Due to its complex nature, it is difficult to capture all aspects of cognitive reserve. It is 
critical to recognize that proxies of cognitive reserve only represent limited aspects of reserve 
itself. Most studies utilize education level and premorbid IQ to assess cognitive reserve; however, 
there are individuals with low education and high cognitive reserve (and vice versa). A significant 
limitation of many proxy measures for cognitive reserve are their subjective nature and 
susceptibility to hindsight bias. 
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Brain reserve represents the structural characteristics that allow the brain to be resilient to 
the effects of aging and pathological insult (Stern 2009, Stern 2012, Stern 2018). It is generally 
thought that with sufficient brain substrate (e.g. larger grey matter volumes, greater synaptic 
density, more elaborate network complexity), the brain is more able to preserve normal functioning 
despite the presence of factors of neurodegeneration. Theoretically, an individual with high brain 
reserve has more to lose before cognitive or functional deficits may become evident. Brain reserve 
has traditionally been estimated with different modalities of structural neuroimaging. Some 
common proxies for brain reserve include intracranial volume, grey matter volume, grey matter 
density, cortical thickness, white matter volume, and white matter integrity. 
The concepts of cognitive reserve and brain reserve can sometimes be difficult to 
disentangle due their fundamental similarities. The most common theoretical distinctions refer to 
brain reserve as the “hardware,” while cognitive reserve is represented as the “software.” Brain 
reserve has clear biological substrates, while cognitive reserve refers to how the substrate may be 
utilized differently. However, this can be further complicated by the idea that higher structural 
integrity is necessary for more efficient processes.  
Brain maintenance refers to the process of maintaining or improving brain reserve over 
time. Examples of brain maintenance include behavioral changes that improve an individual’s 
modifiable risk factors: physical exercise, change to a healthier diet, smoking cessation, adherence 
to therapeutic interventions.  
1.3.3 Compensatory mechanisms  
Functional changes in brain aging can be thought of as compensatory mechanisms 
employed by the brain to maintain cognitive performance in light of age-related structural changes. 
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The extent and efficacy of these compensatory mechanisms can provide resilience and is 
represented as the concept of cognitive reserve. Age-related functional changes can be detected 
with a wide range of imaging modalities, such as electroencephalography (EEG), 
magnetoencephalography (MEG), functional MRI (fMRI), positron emission tomography (PET), 
or optical imaging (e.g. fNIRS). 
The major themes of compensatory mechanisms in brain aging are compensatory 
hyperactivation, dedifferentiation, and posterior-anterior shift. Compensatory hyperactivation 
refers to the phenomenon where older adults demonstrate greater regional activity than younger 
adults in task-based fMRI studies while maintaining the same level of behavioral performance 
(Dumas 2015). Alternatively, dedifferentiation refers to older adults recruiting more brain regions 
than younger adults in task-based fMRI studies while maintaining the same level of behavioral 
performance (Cabeza 2002). Posterior-anterior shift refers to the tendency of older adults to 
increasingly activate anterior regions relative to posterior during task-based fMRI studies.  
1.3.4 Homeostatic model of brain maintenance 
Homeostatic regulation may serve as a potential model of brain maintenance. Homeostasis 
is the ability to maintain stability and equilibrium of a biological system. As a classical example, 
the stability of our body temperature is a consequence of homeostatic processes that coordinate 
the activity of muscles, blood vessels, and sweat glands. When a cold environment decreases body 
temperature, the hypothalamus releases a signal to the skeletal muscles, promoting shivering as a 
mechanism of thermogenesis and a signal to the blood vessels to increase resistance of blood flow 
(i.e., vasoconstriction). Both of these responses minimize heat loss, helping to maintain body 
temperature.  
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Homeostatic dysregulation in multiple systems occur in aging and may also serve as a key 
contributor to the biological mechanisms of aging (Li 2015). While the authors have provided 
evidence in the systems of lipids, immune function, oxygen transport, liver functioning, vitamin 
levels, and electrolyte levels, they suggest that homeostatic dysregulation is not limited to these 
systems and may occur in other systems in aging. Thus, compensatory hyperactivation may 
represent a homeostatic process that serves to maintain the stability of cognition in a changing 
neurobiological environment. Homeostasis in the context of cognition serves to maintain cognitive 
functioning, despite the presence of neurodegeneration.  
However, homeostatic processes can have adverse effects. For example, extreme 
vasoconstriction for an extended period of time can lead to vascular cell loss. Similarly, 
compensatory hyperactivation may lead to glutaminergic excitotoxicity, which may lead to 
neuronal death (Dodd 1994) or the production of Aβ (Palop 2007). Thus, although homeostasis 
can slow the onset of cognitive decline, this may come at the cost of negative side effects that 
weaken the core cognitive infrastructure.  
1.4 Neuropsychiatric Disorders 
While common in older age, certain neuropsychiatric disorders, such as late-life mood and 
anxiety disorders and Alzheimer’s disease, do not represent the normal process of aging. Those 
who become the oldest-old are not necessarily destined to experience these disorders. Instead, 
these age-related neuropsychiatric disorders may reflect different pathological branches in aging.  
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1.4.1 Late-life depression 
Late-life depression (LLD) is a leading contributor to psychiatric and medical morbidity 
and mortality in older adults (Valiengo 2016). Often treatment resistant and recurrent (Lenze 
2000), LLD results in highly prevalent cognitive impairment (~50%) that is persistent even after 
remission of depressive symptoms (Bhalla 2006, Bhalla 2009). Specifically, LLD has been 
associated with a two-fold increase in risk for development of multiple types of dementia, 
including Alzheimer’s and vascular dementia (Diniz 2013, Green 2003).  
 Etiology of LLD is divided into sub-types based on the pattern and age of onset, namely 
late-onset and early-onset LLD. Late-onset refers to the first lifetime episode of depression 
occurring after the age of 65, while early-onset refers to the first lifetime episode of depression 
occurring earlier in life, with potential for longitudinally recurring episodes. The differences 
between late-onset and early-onset depression hold different implications with regards to etiology 
and pathophysiology in their respective cases (Aizenstein 2016, Taylor 2013, Riddle 2017). 
More specifically, early-onset LLD has been associated with a genetic predisposition to 
depressive episodes, as well as potential external stressors such as adverse life events. These 
patients may also have a family history of lifelong depression, and also have an increased lifetime 
cumulative of time spent in depression compared to late-onset LLD patients, and therefore are 
potentially at greater risk for pathophysiologic changes such as hippocampal atrophy and 
decreased brain reserve. 
Late-onset LLD patients on the other had may have greater vascular disease burden as 
explained by the vascular depression hypothesis, which proposes that changes in mood and 
increases in depressive symptoms may arise directly due to cerebrovascular disease leading to 
damage in relevant structural circuits and pathways (Aizenstein 2016, Taylor 2013). Other 
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pathologic processes contributing to late-onset LLD may exist as well, but generally a family 
history of lifelong depression is absent, although genetic predisposition to cerebrovascular disease 
or vascular disease in general may be present. 
1.4.2 Late-life generalized anxiety disorder 
Late-life generalized anxiety disorder (LLGAD) is a difficult disorder to fully characterize 
epidemiologically due to the diverse nature of the disorder among the wide range of experiences 
and presentations which older adults (especially adults in ethnic and racial minority groups) may 
have. However, current estimates suggest that the 1-year prevalence of LLGAD may be as high as 
11.6% for all older adults in the US (Reynolds 2015, Kessler 2005). As with LLD, patients with 
LLGAD are at significantly greater risk for poorer quality of life including increased cognitive 
decline, risk for dementia, and exacerbation of other medical comorbidities. LLGAD itself is also 
associated with increased risk for depression, and represents a significant public health burden, all 
while being significantly underdiagnosed and undertreated (Zhang 2015).  
Reasons for difficulties in identifying and treating LLGAD include camouflage of LLGAD 
symptoms as generalized physiological associations with the aging process, such as decreased 
sleep, difficulty focusing on tasks, and a sense of restlessness. Polypharmacy and medical 
comorbidities may also disguise and confound successful management of these symptoms. Other 
factors include the imprecise nature of patient descriptions of LLGAD symptoms, often resulting 
in psychological, subjective terms being used, as well as the presence of other neurocognitive 
disorders which share significant overlap with LLGAD in symptomology and have comorbidity 
rates up to 71% of all neurocognitive disorder patients (Seignourel 2008). 
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Current management for LLGAD includes a combination of pharmacologic and 
psychosocial approaches. Typical prescribed agents for LLGAD include selective serotonergic 
reuptake inhibitors as well as benzodiazepines, which are accompanied by serious risks for adverse 
events associated with a loss of motor coordination such as falls and motor vehicle accidents and 
are therefore recommended for short-term use only when possible. Psychosocial management of 
LLGAD commonly involves use of cognitive behavioral therapy, which is focused on goal-
oriented, mental thought pattern changing efforts to self-correct maladaptive behaviors in the 
patient. This may often be accompanied with adjuvant therapies including relaxation techniques. 
1.4.3 Alzheimer’s disease  
Alzheimer’s disease (AD) is the most common form of dementia, affecting approximately 
5.8 million people and is the 6th leading cause of death in the United States (Alzheimer’s 
Association 2019). Significant public investment has been made for development of research and 
patient care improvements. There are currently no therapeutic interventions available to treat or 
delay progression of AD. Multiple promising pharmaceutical agents that have reversed the effects 
of AD in animal studies have failed in human clinical trials in AD patients. These trials may have 
been unsuccessful due to the presence of irreversible damage in later stages of AD; thus, it is 
possible that therapeutic intervention applied earlier in the course of AD may be more effective in 
disease modification and/or prevention (Sperling 2011).  
Notably, the pathophysiological processes contributing to AD begin decades prior to the 
onset of clinical symptoms. The period of AD pathophysiological progression prior to cognitive 
symptom presentation is referred to as preclinical AD. Preclinical AD represents a window of 
opportunity for therapeutic intervention given the absence of irreversible damage as seen in the 
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later stages of AD. It is important to note that preclinical AD does not necessarily imply ultimate 
progression to an AD dementia diagnosis. However, should preclinical AD progress in severity, it 
is followed by early mild cognitive impairment (eMCI), late cognitive impairment (lMCI), and 
Alzheimer’s disease (AD). 
There are many reported risk factors for AD, with advanced age serving as the primary risk 
factor in late-onset AD. Conversely, early-onset AD is associated with genetic predispositions to 
AD, as represented by the mutations in amyloid precursor protein (APP), presenilin1 (PSEN1), 
and presenilin2 (PSEN2). Other risk factors for late-onset AD include presence of the 
apolipoprotein E allele, hypertension, hypercholesterolemia, physical inactivity, insulin resistance, 
obesity, poor sleep, traumatic brain injury, epilepsy, late-life depression, and late-life anxiety.  
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2.0 Demonstration of The Effect of Reserve: Late-Life Depression and Increased Risk Of 
Dementia 
This chapter is a modified version of the following manuscript that is currently in submission:  
• Ly, M., Karim, H.T., Becker, J.T., Lopez, O.L., Aizenstein, H.J., Reynolds, C.F. III., 
Zmuda, M.D., Butters, M.A. Late-life depression and increased risk of dementia: a 
longitudinal cohort study.  
 
This work was intended to support Aim 1 as a demonstration of the effect of reserve. In 
this study, our results suggest that the reduction of reserve in patients with late-life depression 
(LLD) increases their risk for developing dementia earlier than their age-matched never-depressed 
healthy controls. My contributions to this project were: analyses, interpretation of the results, and 
drafting and revising the manuscript.  
2.1 Introduction 
Late-life depression (LLD) is a leading contributor to psychiatric and medical morbidity 
and mortality in older adults (Valiengo 2016). Often treatment resistant and recurrent, LLD results 
in highly prevalent cognitive impairment (~50%) that is persistent even after remission of 
depressive symptoms (Bhalla 2006, Bhalla 2009). Specifically, LLD has been associated with a 
two-fold increase in risk for development of multiple types of dementia, including Alzheimer’s 
and vascular dementia (Diniz 2013, Green 2003). However, it is not clear whether individuals with 
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a history of LLD experience a more rapid rate of cognitive decline in light of their increased risk 
of developing dementia. Clarification of the rate of cognitive decline in LLD may provide valuable 
clinical insight into risk stratification and possible prevention of future dementia.  
The heterogeneous and multifactorial etiologies involved present a significant challenge in 
the process of predicting long-term neurocognitive and other outcomes in the course of LLD 
(Alexopoulos 2011, Morimoto 2015). Individuals with LLD present with a wide range of 
variability in neuropathological changes, brain structural abnormalities, and levels of cognitive 
functioning at baseline and following an episode of depression. It is unclear whether these 
abnormalities are related to the etiology of LLD or whether they represent the consequences of 
LLD itself. Clinical attributes, such as depression exposure (length of and number of depressive 
episodes), education level, and medical comorbidity, are also sources of wide variability. A 
potential avenue to reduce heterogeneity in LLD is through stratification of LLD into separate 
phenotypes.  
Age of onset of the first depressive episode is highly related to depression exposure and 
may represent a useful phenotypic distinction. Early-onset depression (EOD) is thought to stem 
from genetic predisposition and adverse life events, while late-onset depression (LOD) is more 
associated with the accumulation of vascular burden and other pathologic aging processes in the 
absence of family history (Aizenstein 2016, Taylor 2013). EOD patients may experience cognitive 
decline due to longer time in depression or more lifetime depressive episodes, which lead to 
hippocampal atrophy, increased allostatic load, and decreased brain reserve. In contrast, cognitive 
decline in LOD patients may result directly from vascular and neurodegenerative risk factors  
(Aizenstein 2016, Taylor 2013). If EOD and LOD represent distinct phenotypes of LLD, it is 
critical to investigate whether cognitive trajectories differ between the two groups over time.   
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Previous investigations of the long-term cognitive trajectories in LLD have largely been 
cross-sectional, while longitudinal studies often did not exceed five years in duration, thereby 
limiting their ability to delineate longer neurocognitive trajectories. Other limitations of prior 
studies include small sample sizes, limited use of highly replicable neurocognitive batteries, and 
lack of measurement and/or statistical control of baseline cognitive functioning. In addition, many 
studies did not differentiate between EOD and LOD in reporting LLD subgroups. One study did 
stratify outcomes in EOD and LOD patients using a robust longitudinal design, but obtained 
baseline neuropsychological measurements while patients were depressed, which potentially 
confounds the interpretation of cognitive performance (Riddle 2017). 
The primary purpose of this longitudinal study was to determine whether individuals with 
a history of LLD experience more rapid cognitive decline than those without a depression history. 
Participants with a history of LLD and never-depressed control (NDC) participants underwent 
annual neuropsychological assessments for up to ten years. Most assessments were made while 
LLD participants were in a state of remission. Baseline cognitive performance and rate of cognitive 
decline were compared between the LLD and NDC groups. We hypothesized that individuals with 
a history of LLD would have more cognitive impairments at baseline and exhibit a more rapid 
decline in multiple domains of cognitive performance compared with the NDC group. We also 
investigated whether dichotomization of the LLD group into EOD and LOD phenotypes revealed 
differing rates of cognitive decline.  
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2.2 Methods  
2.2.1 Participants  
Participants with LLD were recruited from the University of Pittsburgh Late-Life 
Depression Prevention and Treatment Center (N=185), while NDC (N=114) were recruited from 
the local Pittsburgh community. Recruitment occurred on a rolling basis which allowed for more 
data acquisition and longer follow-up from participants recruited in the early years of the study 
and higher retention rates. Inclusion criteria for LLD participants stipulated age 60 or older at 
baseline visit, meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) criteria for unipolar major depression, English language fluency, and visual and 
auditory acuity adequate to undergo neuropsychological assessment. Exclusion criteria included 
major unstable medical illness, diagnosis of psychiatric disorders other than unipolar major 
depression or anxiety disorders, neurologic disorders or injuries with direct effects on cognitive 
functioning, and clinical diagnosis of dementia. Control participants met the same inclusion and 
exclusion criteria, with the exception that they had no lifetime history of psychiatric disorder. 
Lifetime antidepressant exposure was reported in 93.5% (N=173) of individuals with history of 
LLD and 9.6% (N=11) of NDCs for indications other than depression. Over the duration of this 
study, approximately 70% of the LLD group and approximately 10% of the NDC group were 
taking antidepressant medication. LLD participants were further categorized into early-onset 
(EOD, N=85) and late-onset subgroups (LOD, N=100), with early-onset defined as having lifetime 
depressive episode at age 59 or younger and late-onset defined as first lifetime depressive episode 
at age 60 or older. All participants provided informed consent under a protocol approved by the 
University of Pittsburgh Institutional Review Board.  
 22 
2.2.2 Procedures 
At baseline and annual follow-up visits, participants were assessed for depressive 
symptoms (17-item Hamilton Depression Rating Scale, HDRS-17), medical comorbidity 
(Cumulative Illness Rating Scale for Geriatrics, CIRSG), and cardiovascular risk factor status (risk 
factors derived from Probability of Stroke Risk Profile from the Framingham Study). In order to 
ensure that cognitive assessments occurred during a period of reduced depressive symptoms, we 
aimed to test only participants whose HDRS-17 score was ≤ 10 for neuropsychological testing. 
Participants with HDRS-17 score > 10 were referred to treatment, with study visits postponed until 
symptomatic improvement had occurred (postponed by up to 3 months as needed). However, some 
individuals did not remit at one or more visits but were still assessed. Approximately 21% of visits 
[376 out of 1774 total visits across all participants] had a participant with a HDRS-17 score greater 
than 7 (criteria for remission). Amongst those visits, participants had on average 2.3 (SD 1.5) visits 
with a HDRS-17 greater than 7.  
The neuropsychological battery utilized in this study has been well-validated in assessing 
cognitive function across multiple domains in older adults, as detailed in our prior work (Butters 
2004). The raw scores of each neuropsychological test were converted to standard scores using the 
distribution of the comparison group. Composite scores for each cognitive domain 
(Attention/Processing Speed, Visuospatial Ability, Verbal Ability, Executive Functioning, and 
Delayed Memory) were then calculated by averaging the standard scores across tests in Table 2. 
Selection of cognitive domains was guided by factor analysis, conceptual groupings, and 
Cronbach’s alphas. The Cronbach’s standardized alpha values ranged from 0.55-0.75. The 
cognitive diagnosis for each participant was then determined through consensus conferences 
affiliated with the University of Pittsburgh Alzheimer’s Disease Research Center. 
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Table 2. Neuropsychological battery 
Domain Tests Outcome Measure 
Attention/Processing 
Speed 
Digit Symbol Number of correct symbols in 90 
seconds 
Grooved Pegboard Time in seconds to complete for both 
hands 
Trail Making A Time in seconds to completion 
Finger Tapping Average number of taps in 10 seconds 
for both hands 
Visuospatial Ability 
Block Design Score calculated from total number of 
accurate patterns and time to 
completion 
Clock Drawing Number of features drawn correctly 
Modified Rey Osterreith 
Figure 
Copy, number of features drawn 
correctly 
Simple Drawings Number correct 
Verbal Ability 
Semantic Fluency Number of appropriate words listed in 
60 seconds 
Boston Naming Number correct 
Spot the Word Total number of errors 
Letter Fluency Number of appropriate words listed in 
60 seconds 
Executive Functions 
Trail Making B Time in seconds to complete 
Executive Interview Total score 
Stroop Color Word 
Inhibition 
Number of items correct in Color-
Word condition in 45 seconds 
Wisconsin Card Sorting Percentage of errors (total, 
perseverative, and non-perseverative), 
number of categories completed 
Delayed Memory 
Logical Memory Delayed recall, number of details 
correct 
California Verbal Learning 
Test 
Delayed recall, number correct 
Modified Rey Osterreith 
Figure 
Delayed recall, number of features 
drawn correctly 
 
2.2.3 Statistical Analysis 
Prior to any analysis, we examined data distributions to assess normality and the presence 
of outliers. We calculated descriptive statistics for baseline demographics and clinical measures of 
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the NDC and LLD groups, using t-tests to test for group differences on the continuous variables 
and chi-square tests for categorical variables.  
We plotted cognitive domains over time for both groups to examine individual domain 
trajectories as well as the mean (and standard error) for each group. After reviewing the graphs, 
we chose to use 10 years of data in all analyses to maximize clinical relevance and to minimize 
bias estimates due to drop off in sample size and increased variability after 10 years. Baseline date 
and yearly visit dates determined the time variable for all analyses. We employed a mixed-models 
approach to compare domain trajectories and to test for group, time, and group by time differences. 
When fitting the model, we controlled for baseline domain score since the two groups differed at 
baseline. Baseline age, baseline medical comorbidity, education, and sex were also included in the 
model as covariates since these are known to affect cognitive function. Models first considered a 
quadratic effect to test for nonlinear trajectories. When the quadratic component was not 
significant, we moved to a linear model. Best fit model was determined by comparing Bayesian 
Information Criterion (BIC) values between models.  
Attention/processing speed, verbal ability, delayed memory, and global cognitive function 
included both linear and quadratic time as both fixed and random effects. Executive function and 
visuospatial ability included only linear time as fixed and random effects. For comparing between 
subtypes of depression (EOD vs. LOD), only delayed memory had both linear and quadratic time 
as both fixed and random effects, while other domains included only linear time as fixed and 
random effects.  
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2.3 Results 
The demographic and clinical characteristics of the study participants comparing LLD and 
NDC are displayed in table 3. The LLD group compared to NDC was older, had a greater 
percentage of female participants, and had greater medical comorbidity and vascular risk factors 
as determined by the CIRS-G and CVRF, respectively.  
The demographic and clinical characteristics of the study participants comparing LOD, 
EOD, and NDC are displayed in table 4. The LOD group was older than both EOD and NDC; 
there were more women in the EOD group compared to both the LOD and NDC groups; LOD and 
EOD groups had greater medical comorbidity (CIRS-G) than NDC; LOD group had greater 
vascular risk factors than the NDC; and LOD had lower length of follow-up than NDC and EOD.  
 
2.3.1 Comparing LLD and NDC 
At baseline, the LLD group compared to the NDC performed worse in all domains except 
for the visuospatial domain (figure 1). The LLD declined more rapidly than the NDC only in the 
verbal domain, however this difference appears to be related to a lack of a practice effect among 
LLD compared with NDC rather than actual decline – lack of a practice effect is often due to 
cognitive impairment (figure 1).  
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2.3.2 Comparing LOD, EOD, and NDC 
At baseline, the LOD group performed significantly worse than the NDC group in all 
domains. At baseline, all three groups differed (NDC > EOD > LOD) in the attention/processing 
speed and global function domains (figure 2). The LOD group declined more rapidly over time 
compared to the NDC group in verbal ability and delayed memory (figure 2).  
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Table 3. Comparison of LLD and NDC Baseline demographics/follow-up information 
 
 
*Transformation used in analyses.  Means (STD) reported in original units.**Satterwaite 





Table 4. Comparison of LOD, EOD and NDC Baseline demographics/follow-up information.  
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*Transformation used in analyses.  Means (STD) reported in original units.; Values in 
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Figure 1. Graph of cognitive trajectories comparing NDC vs. LLD. 
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There were baseline differences between LLD and NDC in all domains except visuospatial ability. LLD group 
differed over time compared to the NDC in the verbal ability only – this may be due to lack of practice effect 




Figure 2. Graph of cognitive trajectories comparing NDC vs. LOD vs. EOD. 
Graph of cognitive trajectories comparing NDC vs. LOD vs. EOD. At baseline, the LOD group performed 
worse than NDC in all domains while all three groups differed in the attention/processing speed and global 
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function domains (NDC > EOD > LOD). The LOD group declined more rapidly than both the NDC and EOD 
groups in the verbal ability and delayed memory domains. 
2.4 Discussion 
To our knowledge, this study represents one of the first longitudinal studies to utilize a 
broad-based, comprehensive neuropsychological battery to assess cognitive decline in remitted 
late-life depression. We found that at baseline, those with a history of LLD showed cognitive 
impairment across multiple domains and further that those with LOD showed even greater 
cognitive impairment compared to EOD compared to NDC. We also found that those with LOD 
had a more rapid rate of decline in verbal ability and delayed memory compared to NDC.  
Although individuals with a history of LLD did not exhibit a steeper rate of decline 
compared to NDC, they did exhibit significantly greater baseline cognitive impairment. This 
difference could account for the increased incidence or risk of dementia and reflect mixing of EOD 
and LOD subtypes. The prevalent baseline impairment may reflect decreased brain and/or 
cognitive reserve. Brain and cognitive reserve represent protective factors, such as greater cortical 
thickness or high level of educational/occupational attainment, that provide resilience to age-
related decline and other pathological processes (Stern 2012, Stern 2018). LLD has been associated 
with numerous neuropathological abnormalities, including increased inflammation and elevated 
glucocorticoids, which contribute to cerebrovascular injury, amyloid deposition, hippocampal 
atrophy, and reduced volume in the basal ganglia and prefrontal regions (Byers 2011). These 
pathological processes contribute to greater levels of lowered brain and cognitive reserve, thus 
potentially leading those with LLD to cross the threshold of clinical dementia sooner than NDCs.  
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Stratification of LLD into separate phenotypes based on age of onset demonstrated 
different patterns of cognitive impairment and decline. Individuals with EOD, while not exhibiting 
more rapid decline over 5-10 years, did exhibit significant impairment in the attention/processing 
speed and global cognitive function at baseline. Impairment in global cognitive functioning 
provides evidence of the neurotoxicity of depression: repeated, cumulative depression exposure 
can have a significant impact on brain reserve and cognitive function (Byers 2011). In contrast, 
individuals with LOD performed worse than NDC in all domains at baseline and experienced more 
rapid decline in verbal ability and delayed memory than both NDC and EOD. The progressive 
decline in memory performance is especially salient, as it may represent the leading clinical sign 
of impending dementia. Thus, our findings are consistent with the hypothesis that LOD may 
represent a prodromal phase of dementia (Bennett 2014). This provides support to theories that 
suggest LOD may be due a result of aging-related neuropathology, e.g., amyloid, gray matter 
atrophy, and cerebrovascular disease (Aizenstein 2016, Taylor 2013).  
Our findings differ from those reported by Riddle, et al (Riddle 2017). In their study, Riddle 
and colleagues reported that individuals with LLD exhibited more cognitive impairment at 
baseline and greater subsequent decline in all cognitive domains compared with NDC, with EOD 
individuals experiencing greater decline than LOD and NDC groups. Of note, their participants 
were depressed at baseline—possibly a source of unexplained variance in subsequent measures of 
trajectory. Our neuropsychological battery was more broad-based and comprehensive, especially 
in the executive functioning and verbal domains. The Riddle et al.  participants may have 
experienced a different cognitive trajectory than our study sample, being younger (e.g. higher brain 
reserve) and more educated (e.g. higher cognitive reserve) on average than our participants. We 
suggest that the findings in our study are complementary to those of Riddle et al., rather than 
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contradictory, and may capture different perspectives reflecting differences in study samples, as 
well as in content and timing of neurocognitive assessment.  
Our study has several limitations. Although most of the neuropsychological assessments 
were performed while the LLD participants were in a state of remission, a small subset of 
participants had not achieved full remission but were still included in our analyses. Hindsight bias 
in self-reported age of first depressive episode may also limit the accuracy of stratification of LLD 
into EOD and LOD phenotypes. Incorporation of other imaging or metabolic biomarkers (e.g. 
white matter hyperintensities, cortisol levels) may allow for more optimal differentiation between 
EOD and LOD participants. Our study sample was predominantly Caucasian, and thus did not 
reflect the greater medical comorbidity and attendant effects on brain health and cognitive function 
to which African Americans are subject. Differences between groups may be due to sampling bias 
since the depressed participants were recruited from an academic research center, while some of 
the NDC were recruited from the local Pittsburgh community. Consistent with prior studies, effect 
sizes for cognitive decline were modest. While LLD and NDC showed no differences in follow-
up, the individuals with LOD (compared to EOD and NDC) had a shorter average follow-up, which 
may affect the results and is a limitation of our study. Further study with longer follow-up or with 
a lifespan approach may provide insight toward the critical stages of cognitive decline.  
In conclusion, we observed that patients with a history of LLD did not experience an 
accelerated rate of cognitive decline over 5-10 years as compared with NDC. Instead, we observed 
LLD to be associated with greater baseline cognitive impairment, providing a possible explanation 
for the association of LLD with development of dementia. Dichotomization of LLD based on age 
of depression onset yielded different cognitive trajectories over time, suggesting that EOD and 
LOD may represent different neural substrates that increase their risk for development of 
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subsequent dementia. Future studies should focus on the pathophysiological changes that may 
lower brain reserve in individuals with EOD, when cognitive differences are small, and later-life, 
when they are substantial. Furthermore, elucidation of the various neurobiological mechanisms 
that underlie cognitive impairment in EOD (e.g., allostatic load, chronic inflammation) vs. LOD 
(subclinical microvascular disease, Lewy bodies, AD pathology) could inform earlier intervention 
to reduce risk for future dementia.  
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3.0 Demonstration of The Effect of Reserve: Cognitive Reserve Effect in the Extended 
Memory Encoding Network in Subjective Cognitive Decline 
This chapter is a modified version of the following manuscript that is currently under 
review:  
• Mizuno, A., Karim, H.T., Rangarajan, A., Ly, M., Cohen, A.D., Lopresti, B.J., Mathis, 
C.A., Klunk, W.E., Aizenstein, H.J., Snitz, B.E. Cognitive reserve effect in the extended 
memory encoding network in subjective cognitive decline: a functional MRI and 
amyloid-PET study.  
 
This work was intended to support Aim 1 as a demonstration of the effect of reserve. In 
this study, we demonstrated that level of cognitive reserve altered the patterns of functional MRI 
activation during a memory-encoding task in individuals with subjective cognitive decline (SCD). 
These results support the theory that level of cognitive reserve may be a determinant of which 
neural compensatory responses to pathological processes may be employed. My contributions to 





Subjective cognitive decline (SCD) refers to self-experienced decline in cognitive capacity, 
despite objectively measured normal cognitive functioning. It has been suggested that SCD may 
represent an early transition state from normal aging to mild cognitive impairment (MCI) and 
eventually Alzheimer’s Disease (AD) (Buckley et al., 2017; Vogel et al., 2017). SCD symptoms 
are associated with amyloid-β (Aβ) deposition (Amariglio et al., 2012; Perrotin et al., 2012; Snitz 
et al., 2015b). However, the neural characteristics of SCD and the associations with the risk of 
future progression are not well understood.  
SCD is commonly characterized by subjective memory complaints or impairment (Jessen 
et al., 2014). Prior fMRI studies of SCD have largely focused on memory encoding (Erk et al., 
2011; Hayes et al., 2017; Rodda et al., 2009) and have shown SCD-associated hippocampal 
hypoactivation (Erk et al., 2011) and dorsolateral prefrontal cortex (DLPFC) hyperactivation (Erk 
et al., 2011; Rodda et al., 2009). Along with positive associations between DLPFC activation and 
task performance (Erk et al., 2011; Rodda et al., 2009), DLPFC hyperactivation may represent a 
secondary resource to compensate for hippocampal hypoactivation in SCD. Neural compensation 
is postulated to be a process by which additional neural resources are recruited in response to some 
trigger (Stern, 2012). Hyperactivation in SCD may thus occur in response to early AD 
neuropathology (e.g., Aβ) (Garcia-Ptacek et al., 2016). However, the relationship between task-
induced hyperactivation and AD neuropathology has not been directly investigated in SCD.  
To explain individual differences in resilience against risks of dementia, Stern (Stern, 2009; 
Stern, 2012) postulated the cognitive reserve theory: individuals vary in effective maintenance of 
cognitive ability in the face of neural pathology. Cognitive reserve is approximated by proxy 
measures such as education, IQ, literacy, and occupational complexity. The role of education on 
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risk for disease progression in SCD has inconsistent findings in the literature. Fewer years of 
education in SCD was associated with risk of progressing to MCI or AD in a research clinic setting 
(Reisberg et al., 2010). However, in a large population-based study (van Oijen et al., 2007), higher 
education in SCD was associated with greater risk of progression to AD, in contrast to the 
protective effect of education widely observed in other studies (see Sharp and Gatz, 2011 for a 
review).  
This study aimed to 1) characterize the neural basis of SCD symptoms using functional 
magnetic resonance imaging (fMRI) during a well-known memory-encoding task; 2) examine the 
role of Aβ using positron emission tomography (PET) to better understand brain activation in 
relation to emerging AD pathology; and 3) explore how education, a proxy for cognitive reserve, 
may moderate the relationship between brain activation and indices of AD risk (SCD symptoms 
and Aβ). We selected the associative memory encoding (face-name) task because this well- 
validated task has been extensively used to characterize (e.g., (De Vogelaere et al., 2010; Edelman 
et al., 2017; Sperling et al., 2009)) neural functional alterations in AD-related disease.  
3.2 Methods 
3.2.1 Study Design and Participants  
Data for these analyses came from 66 cognitively normal older (mean age = 73.3) 
individuals with varying SCD symptoms. Participants came from two study samples: self-referred 
patient volunteers at an academic memory clinic (n=22) and community-based volunteers for a 
neuroimaging study (n=44). Participants from the memory clinic were approached and recruited 
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after they self-referred for evaluation at the University of Pittsburgh Alzheimer Disease Research 
Center (ADRC). The inclusion criteria for memory clinic participants were: 1) age 60 and older; 
2) clinically significant subjective concern about cognitive changes; 3) normal objective cognitive 
function; and 4) fluent in English. Normal cognitive function was defined as no more than two 
scores falling one standard deviation below age-adjusted norms on a neuropsychological battery, 
and adjudication of normal cognitive function in a diagnostic consensus conference. Community-
based volunteers were recruited through advertisements, and their inclusion criteria were: 1) age 
65 and older; 2) normal objective cognitive function; and 3) fluent in English. All participants 
completed a multi-domain neuropsychological assessment and were reviewed by a diagnostic 
consensus conference that included at least two of the same investigators (authors BES and WEK) 
as the ADRC setting. Exclusion criteria for all participants were: 1) diagnosis of MCI or dementia; 
2) history of significant neurologic or major psychiatric conditions; 3) current medical condition 
or medications that may affect cognitive function; 4) current clinical depression (scored above the 
common clinical cutoff of 15 on Geriatric Depression Scale); and 5) contraindications for MRI or 
PET scans. More detailed descriptions of participants’ criteria were reported previously (Snitz et 
al., 2015a). We excluded one participant due to a poor fMRI coverage in the inferior temporal 
region, with the final sample of n=66. All participants provided written informed consent 
according to protocols approved by the University of Pittsburgh Institutional Review Board.  
3.2.2 Self-Report, Neuropsychological, and Demographic Assessments  
Three measures of self-reported SCD symptoms were used: the Memory Functioning 
Questionnaire (MFQ) (Zelinski et al., 1990); the Cognitive Failures Questionnaire (CFQ) 
(Broadbent et al., 1982); and the Subjective Cognitive Complaint Scale (SCCS) (Snitz et al., 2012). 
 41 
Each scale was transformed into Z-scores using age-adjusted means from published studies 
(Gilewski et al., 1990; Knight et al., 2004; Snitz et al., 2015b) and standard deviations (SD) from 
current participants’ responses. After inverting the MFQ (such that higher values indicate worse 
SCD symptoms), we computed a mean of Z-scores. We defined this composite score as “SCD 
symptoms” and included it in analyses as a continuous variable indicating the SCD symptom 
severity. This continuous measure approach was used in a previous fMRI study in SCD (Hayes et 
al., 2017), and we employed the same approach here to measure brain activation during memory 
encoding associated with the degree of SCD severity.  
We employed modified Rey-Osterrieth complex figure immediate and delayed recall 
scores (Becker et al., 1987) as an index of objective memory performance to complement our 
visual memory- encoding task for the fMRI data. We transformed both scores to Z-scores using 
age-adjusted means from previously published studies (Wolk et al., 2009) and SD from current 
participants’ responses. Then, we defined an objective memory score as a mean of Z-scores. Five 
participants were missing memory test scores due to a change in the neuropsychological test 
battery; these participants were excluded from the corresponding analyses but included for the 
main fMRI analysis.  
Participants self-reported years of education. For post-hoc analysis, we created three 
groups: high school (≤12 years, n=24), some college (>12 and ≤16 years, n=24), and post college 
(>16 years, n=18). Additionally, we measured neuroticism with the NEO Five-Factor Inventory 
(FFI-3) (McCrae and Costa, 2007) and included it as a covariate to account for the influence of 
previously reported high neuroticism in SCD (Kliegel et al., 2005) (details below).  
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3.2.3 Face-Name Association fMRI Task  
We employed the “face-name” association task, which elicits paired associative memory 
encoding (De Vogelaere et al., 2010; Edelman et al., 2017; Sperling et al., 2009) (Supplemental 
Figure S1). Participants saw a face-name pair for 5 seconds and decided whether the name “fit” 
the face – there is no correct answer. Participants responded with their right/left index finger if the 
name fit or not, respectively. Participants were given the following instructions: “Try to remember 
these face-name combinations; you will be quizzed after the scan.”  
During encoding blocks, participants were presented with eight novel face-name pairs, 
while recognition blocks were identical except with familiar face-name pairs (one female and 
one male) learned during a pre-scan session. Faces were presented for 5 seconds each and a 
white plus sign was presented for 1 second after each face. Blocks lasted 48 seconds each and were 
alternated with a 25-second fixation period. Each block repeated twice (5 minutes for 1 run). 
Participants repeated the task three times (i.e., 3 runs) and saw 50 face-name pairs: two familiar 
and 48 novel pairs.  
During the post-fMRI scan test, participants saw a face with two names, one seen in the 
scanner and one new, and were asked to choose the name seen in the scanner. We assessed the 
accuracy of recognition memory as a post-scan recognition score. Two participants were missing 
this score, and for the participants that did not complete all sessions, we ensured that their post- 
scan test used only the faces they saw in the scanner.  
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3.2.4 PET Data Acquisition  
PET data were acquired on Siemens/CTI ECAT HR+ scanner. 15mCi of high specific 
activity (~2.1Ci/μmol at EOS) [11C]PiB was injected intravenously over 20sec. Transmission 




Ga rod sources for attenuation correction. PET 
emission data was reconstructed using filtered back projection with corrections for attenuation, 
scatter, and radionuclide decay.  
3.2.5 MRI Data Acquisition  
MRI data were collected using a 3T Siemens Trio TIM scanner with a 12-channel head 
coil. The whole brain structural sequences were collected: sagittal 3D MPRAGE, axial 2D FLAIR, 
axial 3D T2-weighted sequence (see methods supplement for parameters). An axial EPI BOLD 
(blood oxygen-level dependent) sequence during the face-name association task was collected with 
echo time=32ms, repetition time=2000ms, flip angle=90 , field-of-view=128x128, 2x2x4mm 
resolution with no gap, and GRAPPA (GeneRalized Autocalibrating Partial Parallel Acquisition) 
factor 2. Due to poor coverage and placement, scans covered above the cerebellum up to the motor 
cortex.  
3.2.6 PET Data Analysis  
After inspection for interframe motion, the automated image registration (AIR) algorithm 
(parameters optimized for PET to PET registration) was applied to the dynamic [
11
C]PiB image. 
A summed PET image over the 50-70 minute post-injection interval was calculated for PET-MR 
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image co-registration using AIR after manual reorientation of MRI to AC-PC line (Woods et al., 
1993). The resulting spatial transformation was applied to the summed PiB image and interpolated 
in the MR image space. Six ROIs were separately hand-drawn on a co-registered MRI (Cohen et 
al., 2013; Rosario et al., 2011). Regional radioactivity concentrations from ROIs were transformed 
into units of standardized uptake value (SUV) using the injected dose of PIB and the participant’s 
mass. The SUV was normalized to non-specific uptake (cerebellum as reference), yielding an SUV 
ratio (SUVR) measure that compares favorably to fully quantitative measures of specific 
radiotracer retention (Lopresti et al., 2005). SUVRs were partial volume-corrected using a 
previously validated method (Price et al., 2005). We defined “Aβ deposition” as a global SUVR 
that we computed as the average of six SUVRs, resulting in a continuous variable. We also defined 
participants’ Aβ status as a categorical variable. We classified participants as Aβ positive or 
negative with a sparse k-means cluster analysis method (cutoff = 1.51 global SUVR) (Cohen et 
al., 2013). Three participants were missing PiB-PET data, and these participants were excluded 
from the corresponding.  
3.2.7 MRI Data Analysis 
3.2.7.1 Preprocessing.  
Statistical Parametric Mapping (SPM12) toolbox in MATLAB2016b (MathWorks) was 
used to preprocess MRI data. Structural sequences were co-registered to the MPRAGE, bias-
corrected, segmented into multiple tissue classes that generated a deformation field to normalize 
images to MNI (Montreal Neurological Institute) space. An automatic intracranial volume mask 
was generated using a threshold of 0.1 on gray/white/CSF (cerebrospinal fluid) followed by image 
filling and closing in MATLAB and applied to the MPRAGE to remove skull.  
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Functional data was motion-corrected, co-registered to the skull-stripped MPRAGE, 
normalized (2mm isotropic resolution), and smoothed using a Gaussian kernel with FWHM of 
8mm. We computed five summary measures of motion using ArtRepair toolbox 
(http://cibsr.stanford.edu/tools/human-brain-project/artrepair-software.html).  
We computed the mean volume of the left and right hippocampus using FIRST in FSL 
(FMRIB Software Library) on the skull-stripped MPRAGE. FIRST uses a model-based approach 
to segment subcortical structures using Bayesian shape and appearance models.  
3.2.7.2 Modeling task effect.  
We modeled encoding and recognition tasks (convolved with the canonical hemodynamic 
response function; all runs input into a single model) as well as the mean of the signal and six 
motion parameters from the alignment (independently modeled for each session). The model 
included a high-pass filter (1/128Hz to account for drift, using a series of cosines) as well as an 
autoregressive filter to account for serial correlations due to aliased biorhythms/unmodeled 
activity. We computed the contrast encoding minus recognition. We then conducted a voxel-wise 
one-sample t-test on the parameter estimates in statistical non-parametric mapping toolbox 
(SnPM13). We generated a mask based on this contrast, which was used in subsequent statistical 
analyses to limit the number of statistical tests computed to only regions that were activated by the 
task.  
3.2.7.3 The main effects of indices of AD risk (SCD Symptoms, Aβ deposition).  
We tested voxel-wise associations between brain activation during memory encoding and 
both SCD symptoms and Aβ deposition separately. We used SnPM13 to conduct all voxel-wise 
statistical analyses. This toolbox uses a non-parametric permutation test to calculate p-values for 
 46 
each voxel. We controlled the voxel-wise false discovery rate (FDR) at α<0.05. As an additional 
analysis to assess the effect of task-performance, we tested the voxel-wise association between 
brain activation during memory encoding and post-scan recognition scores.  
3.2.7.4 Moderating role of education (interaction effects).  
We examined whether education moderated the relationship between brain activation 
during memory encoding and either SCD symptoms or Aβ deposition. We tested (voxel-wise) 
interactions between SCD symptoms and education (mean-centered scores) and between Aβ 
deposition and education (FDR at α<0.05 for both). To test the robustness of each interaction to 
nuisance variables (age, objective memory scores, neuroticism, sex, post-scan recognition scores, 
hippocampal volume, recruitment methods, and five in-scanner motion measures), we ran 
regression analyses (in R, https://www.r- project.org) with extracted mean activation (encoding-
recognition contrast) from significant regions with an interaction. In this analysis, participants who 
had missing data in any of these variables were excluded from the robustness testing.  
3.2.7.5 Exploratory analyses.  
By using the same extracted mean activation values, we tested the SCD symptoms by 
education interaction separately for participants classified as Aβ positive (n=27) and those 
classified as Aβ negative (n=36) to explore the effect of Aβ (and an additional 3-way interaction) 
in R.  
To further understand the role of Aβ in SCD symptoms and memory encoding, we 
computed the Pearson’s correlations to assess the association of Aβ deposition with SCD 
symptoms, objective memory, and post-scan recognition scores (and within the two recruitment 
method groups) in R.  
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Table 5. SCD Study: Demographic information 
 
3.3 Results 
3.3.1 Hippocampal Activation for Memory Encoding (Task Effect)  
We observed increased activation in the bilateral hippocampus in anterior (peak coordinate: 
right [24,-10,-12], left [-22,-10,-14]) and posterior (peak coordinate: right [30,-26,-4], left [-26,-
24,-4]) during encoding compared to recognition.  
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3.3.2 No Main Effects of Indices of AD Risk (SCD Symptoms, Aβ deposition)  
We found no significant direct associations between activation and either SCD symptoms 
or Aβ deposition. There was no association between activation and post-scan recognition scores.  
3.3.3 Moderating Role of Education on Activation and SCD Symptoms  
In participants with higher education, greater SCD symptoms were associated with greater 
activation; while in participants with lower education, greater SCD symptoms were associated 
with lower activation. The moderation effect was found in the executive control network (ECN), 
salience network (SN), and subcortical regions (Figure 3 left). For the ECN, we observed 
activations in bilateral DLPFC extending to inferior frontal gyrus (IFG), left inferior parietal lobule 
(IPL) extending to angular gyrus, and dorsomedial prefrontal cortex (dmPFC). For the SN, we 
observed three core clusters of this network [bilateral insula, dorsal anterior cingulate cortex 
(dACC)]. Subcortical regions included the midbrain, vermis, ventral tegmental area 
(VTA)/Substantia nigra (SN), caudate/pallidum, thalamus, and putamen. Education did not 
moderate the association between activation and Aβ deposition.  
Figure 3 plots the associations between activation and SCD symptoms for each education 
group. The highest education group (post-college) had the highest slope, the lowest education 
group (high school only) had the most negative slope. This moderation effect (SCD symptoms by 
education) remained significant when controlling for all nuisance variables [R
2 
=0.37, 
F(15,44)=2.21 p= 0.01]. To check the normality assumption required for the linear regression, we 
ran the Shapiro-Wilk test on the regression residuals, finding them to be compatible with normality 
(W=0.98, p=0.37).  
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3.3.4 Exploratory Analysis: Further Moderating Role of Aβ Deposition  
We found that participants who were Aβ positive showed the same interaction [R
2 
=0.43, 
F(3,24)=2.24 p= 0.002] with similar slopes of association between SCD symptoms and activation 
(Figure 2). However, participants who were Aβ negative did not show a similar interaction [R
2 
=0.15, F(3,31)=0.14 p= 0.17]. The 3-way interaction with Aβ in the linear model was not 
statistically significant [R
2 
=0.37, F(7,55)=0.06 p= 0.73].  
Aβ deposition was positively associated with SCD symptoms [r(61)=0.30, p=0.02] but not 
objective memory [r(58)=0.05, p=0.74] (the same results per recruitment method group; 








Figure 3. Moderating role of education on memory encoding activation and SCD symptoms. 
Left: The significant moderation effect by education on the association between SCD symptoms and brain 
activation was found in the salience network, executive control network, a set of subcortical regions 
(threshold: p < 0.05, FDR). Right: To visualize the moderation effect by education, we plotted the results by 
categorizing education levels (“High School”12, 12<“Some College”16, and 16<“Post College”). The slope 
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Figure 4. Moderation effect of education, separated by amyloid status.  
Analyses for the moderation effect by education on the association between SCD symptoms and brain activation, 
separately for Aβ positive (left) and Aβ negative groups (right). The same significant interaction was found only 
among participants who were Aβ positive interaction [R2 =0.43, F(3,24)=2.24 p= 0.002] but not in Aβ negative 
participants [R2 =0.15, F(3,31)=0.14 p= 0.17]. 
3.4 Discussion 
We examined brain activation during memory encoding and its association with SCD 
symptoms and Aβ, as well as the role of education – a proxy for cognitive reserve. In participants 
with higher reserve (education), greater SCD symptoms were associated with greater activation in 
the executive control network (ECN), salience network (SN), and subcortical regions; however, in 
participants with lower reserve (education), greater SCD symptoms were associated with lower 
activation in the same regions. This interaction was observed in participants who were Aβ positive 
but not Aβ negative. Aβ was not associated with activation during memory encoding. Similar to 





with greater SCD symptoms but not with objective memory. These findings suggest that 
individuals with higher cognitive reserve may recruit an extended neural network in the context of 
emerging signs of AD risk (i.e., SCD symptoms and Aβ).  
3.4.1 Cognitive Reserve in Extended Neural Networks  
Previous fMRI studies using this memory-encoding task have observed engagement of 
extended networks along with hippocampus (Edelman et al., 2017; Sperling et al., 2009). While 
the hippocampus plays a central role in encoding (De Vogelaere et al., 2010), we found an 
extended neural network that may coordinate other aspects of information processing during 
encoding. The ECN is involved in attention, inhibition, and shifting (Niendam et al., 2012). The 
SN selectively transmits subjectively relevant sensory information to higher-order cognitive 
regions (Menon, 2015), facilitating flexible executive functioning. Regarding subcortical regions, 
the thalamus may belong to an extended memory system by connecting frontal cortex and 
hippocampus (Jin and Maren, 2015); basal ganglia is a core structure for reward learning (Schultz 
et al., 2000); and both SN and VTA are involved in detection of salient signals for learning (Menon, 
2015). The combinations of these regions may constitute the conflict monitoring network by 
integrating incoming sensory information and providing feedback control based on outcomes in 
order to produce successful adaptive goal-directed behaviors (2014). In SCD, the subjective 
experience of cognitive decline in daily cognitive activities may reflect higher cognitive load of 
continuously adjusting errors (i.e., conflict) between one’s prediction and outcomes (Mizuno et 
al., 2018).  
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3.4.2 Moderating Role of Education and Possible Neural Compensation  
We investigated the neural basis of SCD symptoms, focusing on the cognitive reserve 
theory to understand individual differences. Greater activation was observed among participants 
with greater SCD symptoms and higher education (Figure 1). This heightened neural recruitment 
during memory encoding may suggest a compensatory process in response to emerging 
pathological changes of brain (Erk et al., 2011; Rodda et al., 2009), manifested as SCD symptoms 
that were positively correlated with Aβ deposition in this study. It may be that lower education 
(lower cognitive reserve) is associated with lower capacity to mount a compensatory response.  
Previous SCD studies (Erk et al., 2011; Rodda et al., 2009) described increased activation 
as neural “compensation” because performance was positively associated with brain activation, 
suggesting that greater activation facilitated memory task performance. Our study did not find an 
association between task performance and activation. However, due to the cross-sectional nature 
of these studies (including this study), it is unclear whether individuals with greater SCD 
symptoms would have had better performance or higher baseline activation prior to onset of SCD 
symptoms. Thus, we cannot distinguish whether greater activation represents neural 
compensation, disrupted over–activation known as dedifferentiation (Han et al., 2009) or 
excitotoxic neuronal damage (Palop et al., 2007). Nonetheless, our study is the first to our 
knowledge to report an indirect relationship between brain activation and Aβ deposition in SCD. 
Figure 3 displays a conceptual model of variables investigated in these analyses and theorized 
directions of influence.  
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3.4.3 Limitations  
In this study, education was the sole index of cognitive reserve, which may limit the 
generalizability of our results. Education is commonly used as a proxy for cognitive reserve (Evans 
et al., 1997; Karp et al., 2004); however, other estimates of cognitive reserve (e.g., literacy (Manly 
et al., 2005), cognitively-engaging leisure activities (Stern, 2012)) should be investigated. 
Moreover, power was limited to detect a significant SCD x education x Aβ 3-way interaction. 
Furthermore, most participants in our ‘lower’ education group were high school graduates. Present 
results, therefore, should be confirmed with larger samples with a broader range of education levels 
and other measures of cognitive reserve. Finally, combining participants from two recruitment 
methods (memory clinic and community study settings) ignores any qualitative differences in 
meaning and significance of SCD symptoms between two samples (Jessen et al., 2014). Future 
studies can address the important factors underlying medical help-seeking behavior as an index of 
AD risk (Slot et al., 2018; Snitz et al., 2015a). 
3.5 Conclusions 
The current study investigated the neural basis of SCD symptom and Aβ deposition effects 
on memory encoding, observing that brain activation depended neither on SCD symptoms nor Aβ 
directly. Rather, level of education moderated the association between brain activation and SCD 
symptoms. Individuals with higher education and greater SCD symptoms displayed greater 
activation, whereas those with lower education and greater SCD symptoms displayed lower 
activation. Greater SCD symptoms may reflect a saturation of neural compensation in individuals 
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with greater cognitive reserve, while it may reflect diminishing neural resources in individuals 
with lower cognitive reserve.  
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4.0 Improving Brain Age Prediction Models: Incorporation of Amyloid Status in 
Alzheimer's Disease 
This chapter is a modified version of the following manuscript that has been published:  
Ly, M., Yu, G.Z., Muppidi, N.R., Karim, H.T., Mizuno, A., Klunk, W.E., Aizenstein, H.J. 
for the Alzheimer’s Disease Neuroimaging Initiative. Improving Brain Age Prediction Models: 
Incorporation of Amyloid Status in Alzheimer’s Disease (In press) Neurobiology of Aging.  
 
This work was intended to support Aim 2 by creating a novel proxy measure of brain 
reserve. In this study, we demonstrated that amyloid status is a critical feature of brain age 
prediction models in the context of Alzheimer’s disease. By training a brain age prediction model 
in amyloid negative individuals, we were able to demonstrate the greatest differences in brain age 
between Alzheimer’s disease diagnostic groups, especially in preclinical Alzheimer’s disease. My 
contributions to this project were: design, analyses, interpretation, and drafting and revising of the 
manuscript.    
4.1 Introduction 
Neuroimaging-based brain age prediction may serve as a promising, individualized 
biomarker of brain health (Cole and Franke, 2017) to understand the highly heterogeneous 
biological changes that occur in aging. Machine learning brain age prediction models learn the 
association between age and neuroimaging data in healthy individuals, where brain age is 
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approximately equal to chronological age (CA) in healthy individuals. Once trained, the brain age 
model may be used in independent samples as a marker of brain health. If the resulting brain age 
is lower than CA, that individual may have a “younger” brain than expected and may be more 
resistant to or have accumulated less pathology. Alternatively, if predicted brain age is greater than 
CA, that individual may have an “older” brain than expected, and may have a genetic 
predisposition, or have experienced a higher cumulative exposure to brain insults. These 
individuals may have been more impacted by pathological insults because of less effective 
homeostatic mechanisms compared with their age-matched peers. Brain age prediction models 
have demonstrated the association of increased brain age with cognitive impairment, Alzheimer's 
disease (AD), traumatic brain injury, Down's syndrome, HIV, and more (Beheshti et al., 
2018, Cole et al., 2015, Cole et al., 2017, Gaser et al., 2013, Liem et al., 2017). 
Prior brain age models have been limited because of the inclusion of amyloid-positive older 
participants in the training sets. It has been demonstrated that amyloid beta (Aβ) deposition, which 
is a hallmark of AD, may occur decades prior to the clinical onset of AD (Jack et al., 2013, Sperling 
et al., 2011). However, the neurotoxic effects of amyloid may be exerted on the brain for years 
before manifestation of overt cognitive impairment (Aizenstein et al., 2008). In this period of time 
before cognitive symptoms appear, Aβ(−) and Aβ(+) individuals demonstrate subtle structural or 
functional differences, such as gray matter (Mattsson et al., 2014) and white matter atrophy (Vipin 
et al., 2019), cerebral hypometabolism (Bozoki et al., 2016), disruptions in gray matter networks 
(Ten Kate et al., 2018), default mode network, and the central executive network (Lim et al., 2014). 
It is possible that brain age models not accounting for amyloid status in the training set (Aβ-
insensitive models) may not detect these very subtle differences and distinguish between 
individuals in these stages.  
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Therefore, we trained a brain age model with only cognitively normal (CN), Aβ (−) 
individuals to potentially improve the utility of brain age as a biomarker in the context of aging 
and AD. We then applied multivariable regression modeling to examine for differences between 
AD cognitive diagnostic stages, as well as amyloid status among cognitively healthy participants. 
In addition, we compared our results against brain ages obtained from a well-known but amyloid-
insensitive brain age model (Cole et al., 2015, Cole et al., 2017). We hypothesized that the 
association between brain age and CA would be moderated by the group—specifically we 
hypothesized that the Aβ(+) group would have a greater positive association between brain age 
and chronological age as compared with the Aβ(−) group indicating a more rapid aging process 
(cross-sectionally). We further hypothesized that more severe diagnostic groups (CN < early mild 
cognitive impairment [EMCI] < late mild cognitive impairment [LMCI] < AD) would have more 
rapid associations between brain and CA. 
4.2 Methods 
4.2.1 Data cohorts 
This study included a total of 1256 structural magnetic resonance imaging (MRI) scans 
from a combination of publicly available databases. All scans were acquired using standard T1-
weighted sequences.   
Databases used for this study were: [Alzheimer’s Disease Neuroimaging Initiative (ADNI); 
Information eXtraction from Images (IXI); Open Access Series of Imaging Series: Longitudinal 
Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer’s Disease 
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(OASIS-3)] and data acquired at the University of Pittsburgh [“Amyloid Pathology and Cognition 
in Normal Elderly” (AG025516; PI: Klunk, Aizenstein)].  
ADNI was designed to test whether serial MRI, positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessments could be combined to 
measure the progression of mild cognitive impairment (MCI) and early AD (www.adni-info.org). 
The IXI dataset consists of nearly 600 MR images from healthy individuals across the life span 
and was collected as part of the project EPSRC GR/S21533/02 (https://brain-development.org/ixi-
dataset). OASIS-3 is a retrospective compilation of data for over 1000 participants that were 
collected across several ongoing projects through the Washington University in Saint Louis Knight 
ADRC over the course of 30 years (https://www.oasis-brains.org). 
The cohort of participants from the University of Pittsburgh were cognitively normal 
individuals between the ages of 60-85 recruited from the local community (previously described 
in Aizenstein 2008). These participants are currently followed longitudinally to assess progression 
in amyloid and tau deposition, alterations in structural and functional MRI, and cognitive 
functioning. All participants provided informed consent, with the approval of the Human Use 
Subcommittee of the Radioactive Drug Research Committees and the Institutional Review Board 
of the University of Pittsburgh. 
4.2.2 Training set 
The training set consisted of 757 images from healthy, Aβ(−) individuals from the ADNI 
(n = 92, mean age: 73.9, range: 60–85, 3T), Information eXtraction from Images (n = 264, mean 
age: 34.9, range: 20–49, 1.5 and 3T), and OASIS-3 (n = 401, mean age: 66.0, range: 42–85, 3T) 
data sets. Inclusion criteria were the age range of 20–85, normal cognitive function, and sustained 
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global amyloid negativity on positron-emission tomography (PET) over at least 3 years (only for 
participants of age 50+ years because detectable amyloid deposition is almost nonexistent in 
individuals without genetic mutations aged <50 years). The earliest corresponding T1 with 
negative amyloid status was selected for use in the training set. Participants were excluded for 
cognitive impairment, memory complaint, dementia, history of psychosis or neurologic disorders, 
and contraindications to MRI and PET imaging. 
4.2.3 Test sets 
The test sets (Table 6, 7) consisted of 491 3T T1 images from 6 groups: (1) CN and Aβ(−) 
individuals from the ADNI data set (CN-Aβ(−), n = 51); (2) CN, Aβ(−) individuals from the 
Pittsburgh community data set (CN-Aβ(−) PITT, n = 32); (3) ADNI CN, Aβ(+) individuals (CN-
Aβ(+), n = 51); (4) ADNI EMCI individuals (n = 195); (5) ADNI LMCI (n = 88); and (6) ADNI 
AD individuals (AD, n = 74). The CN-Aβ(−) group was used as an independent validation set for 
the model. All participants were between the age of 60 and 85 years. All CN-Aβ(−) individuals 
sustained Aβ-PET negativity over 3 years, whereas CN-Aβ(+) individuals demonstrated Aβ-PET 
positivity. The CN-Aβ(−) PITT cohort was included as an additional community-based 
comparison against the ADNI CN cohorts. All CN cohorts were matched by age (mean age 
matched). EMCI, LMCI, and AD groups were all Aβ(+) and are described in ADNI protocols. No 
test set participants were used in training of the model. 
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Table 6. Diagnostic test set characteristics. 
Demographic characteristics and predicted brain ages for both brain age models for cognitive stage test groups are 
shown. Demographic features were compared between groups with one-way analysis of variance or chi-square 




4.2.4 Image preprocessing 
Using the Statistical Parametric Mapping (SPM12) software package, structural images 
were segmented into tissue classes (gray, white, cerebrospinal fluid, skull, soft-tissue, and air). We 
used the nonlinear DARTEL (fast diffeomorphic registration) algorithm to register images to the 
Montreal Neurological Institute space and then generated a template per cohort, and then smoothed 
with a 4 mm smoothing kernel. 
4.2.5 Machine learning model creation and validation 
The Pattern Recognition for Neuroimaging Toolbox (Schrouff et al., 2013) was used to 
create the machine learning model. Whole brain, voxel-wise gray matter densities were mean-
centered and then were used to compute a similarity matrix kernel—in particular we used the 
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simple dot product (this is an N × N matrix that estimates the distance or similarity between any 2 
participants). This matrix was used in a Gaussian Processes Regression model with the similarity 
matrix as the independent variable and chronologic age as the dependent variable with cohort (i.e., 
ADNI, Information eXtraction from Images, or OASIS-3) as a covariate. Accuracy of the machine 
learning model was assessed by running a 10-fold cross-validation on the training set. We 
permuted CA (500 permutations) to assess the significance of the model prediction. Because each 
fold may result in slightly different models, the final overall model was an average of the 10-fold 
cross-validation. This average model was then tested on a separate independent test set of CN-
Aβ(−), which served as a hold-out test set. We also assessed the validity of brain age prediction by 
comparing brain age between CN-Aβ(−), CN-Aβ(−) PITT, CN-Aβ(+), EMCI, LMCI, and AD 
participants. The CN-Aβ(−), CN-Aβ(−) PITT, CN-Aβ(+), EMCI, LMCI, and AD participants were 
not part of the training in any way. 
4.2.6 Comparison against amyloid insensitive brain age model 
We also computed brain age using a model that has been previously described, validated, 
and widely implemented in previous literature which does not account for amyloid status in its 
training (Cole et al., 2015, Cole et al., 2017). Code for the model was downloaded 
from https://github.com/james-cole/brainageR. This was used to estimate predicted brain age 
based on each participant's gray matter and white matter data. We used this brain age measure as 
an amyloid-insensitive brain age compared with our model that accounted for amyloid. 
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4.2.7 Statistical analysis 
All statistical analyses were conducted in JMP Pro 14.1.0 (SAS Institute Inc, 2018). 
Multivariable regression modeling was used to determine the effects of CA, group, and CA-group 
interactions on brain age. This was performed for the AD cognitive diagnostic stages (CN, EMCI, 
LMCI, and AD), as well as CN subgroups of differing amyloid status (CN-Aβ(−), CN-Aβ(−) PITT, 
CN-Aβ(+)). Nonsignificant interactions were removed from the final model. Values of r, R2, and 
mean absolute error (MAE) were evaluated for the goodness of fit of the model. The same analyses 
were performed on the results of the amyloid-insensitive model. 
Difference between brain age and CA has been previously used to identify differences; 
however, recently it has been shown that the strength of the correlation between brain age and CA 
does not guarantee that the difference will be estimated accurately (Smith et al., 2019). 
Furthermore, the difference between brain age and CA is not orthogonal to CA—this means that 
factors correlated with age may be falsely associated with difference between brain and CA (Smith 
et al., 2019). By modeling brain age statistically with CA as a predictor, we circumvent the need 
to compute this brain age and CA difference. This also allows for quadratic associations with CA 
to be modeled (we did not do this here). 
4.2.8 Cross-validated prediction of groups using logistic classifier 
To help understand the predictive potential of these features, we trained a simple logistic 
classifier for predicting the groups (CN-β(−), CN-Aβ(+), EMCI, LMCI, and AD) using the 
following: CA alone; brain age alone; and CA and brain age. Because there are a high number of 
individuals in the EMCI group, we decided to include 30 participants from each group to help 
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balance our logistic classifier (as to not overfit on EMCI). We conducted following analysis 500 
times: (1) choose a random set of 30 participants from each group; (2) train the logistic classifier 
on this training set of 150; and (3) output predictions on other individuals not in training set. We 
then computed the average prediction for each participant across the 500 repetitions. We then 
evaluated the model's performance based on area under the curve (AUC), accuracy, sensitivity, 
and specificity. Because the number of participants in the EMCI group is large, we needed a 
baseline model to help understand what performance we need to improve on. We used the ZeroR 
model, which predicts groups by choosing the most common category (i.e., each participant is 
identified as EMCI)—this is a baseline model that evaluates how good of an accuracy, sensitivity, 
and specificity we need to improve on chance prediction. We describe this model in Figure 5. We 
conducted the same predictions using the Cole model as well. 
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Figure 5. Cross-validated logistic classifier model. 
We fit a cross-validated logistic classifier model for each of the following features: chronological age alone, brain 
age alone, and both features combined to evaluate their performance in predicting group. For each feature set, we 
conducted the following analysis 500 times: 1. choose 30 participants per group randomly (to equally represent 
groups); 2. Fit simple logistic classifier; 3. Predict group on held out test set; 4. Model outputs a single probability 
per group (class) across all repetitions (except for repetitions where participant was part of training set); 5. Calculate 
average probability per group (class); and 6. Evaluate model performance metrics. Once this is done for each feature 
set, the last step is to 7. Compare the feature sets predictive capacity (i.e., identify which features are most ideally 
suited for predicting groups). 
4.3 Results 
Cognitive groups differ by sex, CA, and education. The CN-Aβ(−), CN-Aβ(−) PITT, and 
CN-Aβ(+) groups do not differ by CA but do differ by education. 
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4.3.1 Brain age model prediction: training and independent validation sets 
In our training set, our model accurately predicted brain age (r (756) = 0.94, p < 0.002; 
R2 = 0.88; and MAE = 4.9 years) (Figure 6). We also show that this model does not violate any 
assumptions (Figure 7). In the ADNI CN-Aβ(−) independent validation set, our model also 
accurately predicted brain age (r (50) = 0.64, R2 = 0.42, and MAE = 3.7 years). The model also 
accurately predicted brain age in the entire test set (r (490) = 0.60; R2 = 0.36; and MAE = 
4.65 years). The voxel-wise coefficients of the model that predict CA are shown in Figure 8. 














ADNI (N = 92)
IXI (N = 264)
OASIS-3 (N = 401)
 
Figure 6. Cross-validated brain age predictions for the training set. Plot of 10-fold cross-validated brain age 
with chronological age. 
Depiction of accurate brain age prediction in a training set of cognitively normal, Aβ(-) participants (n=757), with 
r(756) = 0.94, R2 = 0.88, and mean absolute error (MAE) = 4.9 years. Dotted black line indicates identity (brain age 





Figure 7. Diagnostic plots for association between brain age and chronological age in the training set. 
(Top Left) Predicted values vs. standardized residuals indicate that our assumption for linearity is met, however 
there is a dip near age 50 due to the poor number of participants in that age range. (Top Right) Spread-location plot 
with predicted values vs. square root of the absolute value of the standardized residuals indicates homoscedasticity. 












































































Figure 8. Cross-validated (average) coefficients for the brain age model. 
Voxel-wise coefficients that predict chronological age. Positive values (red to yellow) indicate small to large 
positive associations with chronological age and negative values (dark blue to light blue) indicate small to large 
negative associations with chronological age. There is a supplementary file that contains voxel-wise coefficients that 
can be visualized with imaging software. 
 
4.3.2 Multivariable linear regression model between brain age and CA with group effects 
For the Aβ (−) trained model results, the diagnostic group (CN, EMCI, LMCI, and AD) 
was significantly associated with BA even after adjusting for race, sex, and education (F (3, 487) = 
62.3, p < 0.0001, Figure 9, Table 7). Pairwise post hoc group comparisons identified significant 
differences between groups: (1) the CN had a lower brain age compared with EMCI, LMCI, and 




LMCI and AD [age by group interaction]; and (3) LMCI had a lower brain age compared with 
AD. For the Aβ(−) trained model results, CN subgroups (CN-Aβ(−), CN-Aβ(−) PITT, CN-Aβ(+)) 
were significantly associated with BA even after adjusting for race, sex, and education (F (2, 
131) = 3.3, p = 0.04, Figure 9, Table 7). The CN-Aβ(−) PITT had a lower brain age compared with 
CN-Aβ(+), but there were no differences between CN-Aβ(−) and CN-Aβ(+) (Figure 9). 
For the Aβ-insensitive model results, the diagnostic group (CN, EMCI, LMCI, and AD) 
was also significantly associated with BA (F (3, 487) = 6.9, p < 0.0001, Figure 9). However, post 
hoc group comparisons showed that EMCI had greater brain age compared with CN, LMCI, and 
AD. Although there were significant differences between CN and EMCI, incremental differences 
between stages did not follow AD progression (CN to EMCI to LMCI to AD). In addition, there 





Figure 9. Multivariable linear regression for brain age models show benefits of Aβ(-) training. 
Plots for the test group regression lines of brain age over chronological age for both the Aβ insensitive and Aβ(-) 
trained models are shown for AD diagnostic groups (top) and amyloid status in the CN group (bottom). An identity 
line is also provided (dotted black). The Aβ(-) trained model shows incremental differences between diagnostic 




Table 7. Aβ(-) trained brain ages show significant differences between AD diagnostic groups and amyloid 
status in CN participants. 
Results of the multivariable linear regression analysis of the Aβ(-) trained model are shown for cognitive diagnostic 
groups and amyloid status as a sub-analysis of the CN group. The reference test group was CN for comparison 
between diagnostic groups and CN-Aβ(-) PITT for CN subgroups. (CA = chronological age) 
 
4.3.3 Cross-validated simple logistic classifier 
The baseline model (ZeroR), which predicts groups by choosing the most common 
category, had an accuracy of 42%, sensitivity of 21%, and specificity of 80%. We found that CA 
alone has an accuracy of 32%, sensitivity of 24%, and specificity of 82% with an AUC of 0.61. 
We found that brain age alone improves on this with an accuracy of 41%, sensitivity of 34%, and 
specificity of 84% with an AUC of 0.66. Finally, those 2 features together had an accuracy of 42%, 
sensitivity of 42%, and specificity of 85% with an AUC of 0.71. We have plotted receiver-
operating characteristic curves in (Figure 10). Using brain age from the Cole model, we found an 
accuracy of 17%, sensitivity of 19%, and specificity of 80% with an AUC of 0.56. Using brain age 
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from the Cole model combined with CA, we found an accuracy of 32%, sensitivity of 22%, and 
specificity of 82% with an AUC of 0.62. 
 
Figure 10. ROC curve. 
ROC curves for the three logistic models fit: (Top Left) Chronological Age alone as a feature; (Top Right) Brain 
Age Alone as a feature; and (Bottom Left) Both Chronological and Brain Age as features. The dotted black line 
indicates uninformative classifiers. There are as many ROC curves as there are comparisons between groups (i.e., 








































Chronological and Brain Age
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4.4 Discussion 
We trained a brain age model on individuals without significant amyloid pathology to 
improve the utility of brain age as a potential biomarker in aging and AD. Our model predicted 
brain age with similar accuracy as compared with previous brain age models (Beheshti et al., 
2018, Cole and Franke, 2017), both in cross-validation and in the independent test set. The 
resulting brain ages significantly distinguished between diagnostic stages of AD (CN, EMCI, 
LMCI, and AD). 
Although our model distinguished between all stages of AD diagnoses, later stages showed 
increasing differences in BA over CA, suggesting that later AD progression results in exacerbated 
structural changes (as supported by Jack et al., 2013, Sperling et al., 2011). 
The slope of the EMCI line was significantly higher than those of LMCI and AD, 
suggesting that in this stage specifically, BA reflects the greatest extent of structural change over 
time relative to other diagnostic stages. The other stages with similar slopes may reflect 
incrementally increased disease burden or diminished reserve rather than “accelerated aging,” 
although a longitudinal study would be needed for further interpretation. 
For the CN groups, our model was able to significantly distinguish between the CN-Aβ(−) 
PITT and CN-Aβ(+) groups, but not the CN-Aβ(−) and CN-Aβ(+) groups. This may be attributed 
to the Pittsburgh cohort being recruited from community-dwelling older adults for a normal aging 
study, whereas the ADNI cohort has been recruited from Alzheimer's Disease Research Centers 
Alzheimer A, which may include individuals with subjective cognitive decline or other factors not 
accounted for in exclusion criteria, which may warrant additional study. 
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To our knowledge, our model demonstrates the greatest incremental differences in BA over 
CA between diagnostic stages of AD disease progression. In addition, it is the first to consider 
amyloid status in defining the BA prediction model. Notably, a prevailing amyloid-insensitive 
brain age model was not able to correctly order the diagnostic stage test groups or distinguish 
between any CN subgroups. Although comparisons between additional amyloid-insensitive 
models are warranted, these preliminary results show strong potential for the consideration of 
amyloid status in training of brain age models. 
In addition, our results demonstrate that there is potential clinical utility of machine-
learning brain age models in the monitoring of AD. When considering that MRI is relatively 
inexpensive and noninvasive relative to PET and is commonly obtained in cases of subjective 
cognitive concern without objective memory impairment, more developed models may offer 
benefits in tracking disease progression and informing decision making regarding PET imaging. 
Our two-feature (CA and brain age) simple logistic classifier was capable of predicting groups, 
indicating their capacity as predictive features. We noted that brain age improved classification of 
groups with CA. 
One limitation of this study is the diminished correlation coefficient in the independent 
validation set (r = 0.64, compared with r = 0.94 in the training set). The diminished value may be 
explained by the lower number of participants in the test set (51 vs. 757 in the training set) and the 
restricted age range of the test sample (60–85 years compared with 20–85 years in the training 
sample), which reduced the total variability that can be explained by the model (Bland and Altman, 
2011). We also did not evaluate longitudinal changes in cognitive function or amyloid positivity—
future longitudinal studies are needed to evaluate these associations. 
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Regardless, the MAE of our independent validation set is comparable to previously 
published brain age models (Cole and Franke, 2017), which is a better indicator of model accuracy. 
Furthermore, a prior study demonstrated a similar diminished correlation coefficient and preserved 
MAE (Beheshti et al., 2018) with a similar age range. Another limitation of this study is the 
sparsity of participants between the ages of 45 and 55 years as compared with other age groups. 
This is expected, as amyloid-PET is not often acquired in those younger than 60 years. 
4.5 Conclusions 
Our Aβ(−) trained model performed superior to a contemporary Aβ-insensitive model in 
both fitting BA for CA and distinguishing between groups of different stages of AD progression. 
Overall, incorporation of amyloid status in brain age prediction models may improve model 
performance and the utility of brain age as a biomarker of aging and AD. 
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5.0 Application of Brain Age: Accelerated Brain Aging in Chronic Low Back Pain 
This chapter is a modified version of the following manuscript that is currently in 
submission:  
Yu, G.Z.*, Ly, M.*, Karim, H.T., Muppidi, N., Aizenstein, H.J., Ibinson, J.W. Accelerated 
brain aging in chronic low back pain. *co-first authors. 
 
This work was intended to support Aim 3 by applying the brain age prediction model in 
cohorts with age-related neuropsychiatric disorders. In this study, we demonstrated that with 
increasing participant age, greater differences in brain age were found between individuals with 
chronic low back pain (CLBP) and healthy participants. These results suggest that CLBP may be 
associated with a form of accelerated brain structural aging. My contributions to this study were: 
design, analyses, interpretation, drafting and revising the manuscript.  
5.1 Introduction 
Low back pain (LBP) is the leading cause of disability worldwide. Most adults are likely 
to suffer from LBP during some point in their lives, and the number of years lost to disability from 
this condition has increased by 54% since 1990 (Hartvigsen et al., 2018). LBP is highly prevalent 
and challenging to manage clinically. In most cases, the specific source of pain cannot be 
identified, resulting in classification as non-specific LBP (Buchbinder et al., 2018). In addition, 
LBP is often accompanied by and exacerbates medical comorbidities, requiring additional care for 
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poorer treatment response (Foster et al., 2018). Lastly, LBP is highly persistent, with 
approximately two-thirds of patients still reporting pain after twelve months (Meucci et al., 2015). 
There is a mounting body of literature suggesting that chronic LBP (CLBP) may have 
detrimental effects on brain structure. These alterations in brain structure may result in symptoms 
that extend beyond nociception, leading to impairment in attention, mental flexibility, language 
skills, and emotional decision making (Buckalew et al., 2010; Ivo et al., 2013; Malfliet et al., 2017; 
Wand et al., 2011).  
Specifically, CLBP has been associated with changes in gray matter density in multiple 
regions, namely the prefrontal cortex, thalamus, brainstem, corpus callosum, and total gray matter 
volume, although the direction of these changes has been conflicting in various studies (Apkarian 
et al., 2004; Buckalew et al., 2010; Ivo et al., 2013; Kregel et al., 2015; Schmidt-Wilcke et al., 
2006). Past studies have shown that these differences in gray matter are normalized following 
treatment (Seminowicz et al., 2013; Seminowicz et al., 2011).  
We have previously developed and validated a machine-learning based approach to analyze 
global gray matter density to generate a predicted brain age (BA). BA indicates the relative 
structural discrepancy between the subject compared to age-matched healthy peers and has 
recently been shown to have significant promise as a surrogate measure of brain health and 
structural integrity (Ly et al., 2019). This measure may be more sensitive to small changes in 
anatomy and may help in the monitoring and treatment of patients.  
Previously, application of brain age prediction to general chronic pain has shown 
significant differences in predicted age discrepancies between chronic pain patients and healthy 
participants (Cruz-Almeida et al., 2019). However, whether these differences hold true specifically 
in CLBP patients is yet unexplored. Therefore, in this study we applied our brain age prediction 
 78 
model to a cohort of CLBP patients without depression. Since it has been suggested that chronic 
pain may result in “accelerated aging” of the brain, we hypothesized that CLBP patients would 
present with higher BA for their actual chronologic age than healthy controls. In addition, we 
investigated the association between BA and factors of CLBP duration and pain severity at the 
time of imaging for CLBP group.  
5.2 Methods 
5.2.1 Study Design and Participants. 
This study included data from 63 participants, with 31 having CLBP and 32 healthy 
controls (HCs), from the Pain and Interoception Imaging Network 
(https://www.painrepository.org/repositories/). Participants with CLBP were included if they 
(state inclusion and exclusion criteria). (symptoms, other comorbidities, medications, substance 
abuse, volunteer consenting information).  
5.2.2 Data Collected.  
CLBP duration was self-assessed in years. The visual analog pain scale was used to assess 
pain on the day of the MRI scan. Depressive symptoms were self-scored using the Beck Depression 
Inventory (Beck et al., 1996). 
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5.2.3 MRI Data Collection.  
All scanning was conducted at the Northwestern University Feinberg School of Medicine 
by the Apkarian lab on a 3T Siemens Trio TIM research-dedicated scanner (Munich, Germany) 
with an 8-channel head coil. An axial whole brain high-resolution (1mm3 isotropic) T1-weighted 
sequence (magnetization prepared rapid gradient echo, MPRAGE) was collected (TR = 2300 ms, 
TE = 3.43 ms, TI = 900 ms, FA = 9°) with a field of view 256 × 256 with 160 slices. 
5.2.4 MR processing.  
All processing was conducted in SPM12 
(https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Structural MRI scans skull signal had been 
manually removed for de-identification. After bias correction, we conducted segmentation into 
three tissues: gray matter, white matter, and cerebrospinal fluid. We then used the nonlinear 
DARTEL (fast diffeomorphic registration) algorithm to register images to the Montreal 
Neurological Institute (MNI) space then generated a template for this cohort, and then smoothed 
with a 4 mm smoothing kernel (Ashburner, 2007). This process generates a gray matter density 
map – a factor associated with both gray matter volume and cortical thickness.  
5.2.5 Brain Age Model and Estimation.  
We have previously developed a BA estimation algorithm that estimated chronological age 
from gray matter density maps (Ly et al., 2019). Additional details regarding the model and 
databases used in the model training set may be found in the supplement. Brain age for each 
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participant in the CLBP and HC groups was calculated using our algorithm and mean-centered for 
each group. 
5.2.6 Statistical Analysis.  
All statistical analyses were conducted in JMP Pro 14.1.0 (SAS Institute Inc., 2018). 
Outliers were identified as values outside 1.5 interquartile ranges for age or having an absolute 
studentized residual of predicted brain age greater than 3.5 years. As a result, three participants in 
the CLBP group and two in the healthy controls (HC) group were not included for statistical 
modeling. To test for the effect of CLBP on the association between chronological age and 
predicted brain age, a multivariable linear regression was used. We also tested if sex moderated 
this association, as sex has been a significant distinguishing factor in the etiology, prevalence, and 
risk of disability from CLBP (DePalma et al., 2012; Dixon and Gatchel, 1999; Munce and Stewart, 
2007).  Additionally, due to possible interactions of sub-clinical depressive symptoms with CLBP, 
we tested if pain duration in years, current pain (VAS), or depressive symptoms (as characterized 
by the Beck Depression Inventory) moderated the association between chronological age and 
predicted brain age specifically within the CLBP group.  
5.3 Results 
Compared to the healthy control group, the CLBP group was not significantly different in 
participant age or sex, but had significantly greater current pain, pain duration, and depressive 
symptoms (Table 8).  
 81 
Overall, the multivariable linear model predicted BA well (r(62) = 0.57, R2 = 0.32, RMSE 
= 3.46). Group moderated the association between chronological age and BA (corrected model – 
F(5,62) = 6.93, p < 0.001, Table 9). There was a significant interaction effect between CLBP status 
and chronological age on predicted brain age (p = 0.031, Table 9, Figure 11). Sex was not 
associated with BA and did not moderate the association between chronological and brain age.  
Within the CLBP group, none of these factors were directly associated with BA: sex, 
current pain, pain duration, and depressive symptoms (Table 10).  
 
Table 8. Demographic information and differences between experimental groups are shown. 
CLBP – Chronic low back pain; HC – healthy controls; VAS – Visual analog scale for pain; BDI – Beck Depression 
Inventory. 
 
Table 9. Statistical results for multivariable linear regression model testing the effect of group on the 
association between chronological age and predicted brain age. 
The dependent variable was brain age and the healthy control group was used as reference. 
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Table 10. Statistical results for multivariable linear regression model testing the association between the 
difference between brain and chronological ages and factors of sex, current pain, pain duration, and 
depressive symptoms for the CLBP group. 
 
 
Figure 11. Association between chronological age and predicted brain age in healthy controls (HC, blue) and 
those with chronic lower back pain (CLBP, red). 
Trendlines and 95% confidence intervals (shaded areas) are shown. 
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5.4 Discussion 
In this study we sought to apply a machine learning-based brain age prediction model to a 
CLBP cohort without depression with age and sex matched healthy controls. Given the various 
documented deleterious effects of CLBP on brain structure, we hypothesized that the CLBP group 
would have older predicted BA for a given chronological age compared to the HC group. Our 
results supported this hypothesis, as CLBP participants showed an additional 0.145 years in 
predicted brain age per chronological year of life compared to their healthy counterparts.  
Although the precise source of this difference is not known, the greater slope of the CLBP 
brain age to chronological age trendline against the HC line (and therefore a greater discrepancy 
between the two at greater ages) supports previous models regarding CLBP as a form of 
accelerated aging. Many of the changes in brain structure seen in CLBP, such as decreased gray 
matter density in the prefrontal cortex, thalamus, and brainstem, are also seen in the natural aging 
process (Apkarian et al., 2004; Ivo et al., 2013; Kregel et al., 2015). In addition, the upward 
translational shift in the CLBP relationship between brain age and chronological age likely 
indicates the greater disease burden similar to that previously seen in our application of the model 
to cognitive stages in Alzheimer’s disease (Ly et al., 2019). 
In addition, due to the greater slope of the CLBP trendline, the discrepancy in brain age 
between the two groups would theoretically be larger at greater chronological ages, although this 
was not followed longitudinally in this study. This possibly suggests that older adults with CLBP 
are at risk for the greatest brain morphometric changes given their longitudinal pain burden. As 
emphasized by previous studies, there are numerous significant differences in brain structure and 
function in older adults with CLBP compared to their healthy counterparts (Buckalew et al., 2010). 
Especially relevant to the present study is that changes in brain structure associated with late-onset 
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depression were seen even in non-depressed CLBP participants, suggesting that an absence of 
depression does not preclude the structural changes and increased vulnerability to psychiatric 
comorbidities. Previous literature has also shown that degenerative brain changes in older CLBP 
patients are distinct from younger CLBP patients, and that older adults are unable to effectively 
respond to pain due to age-related changes in areas of central pain regulation (Apkarian et al.; J. 
Karp et al.).   
We found that sex, depressive symptoms, duration of pain, and current pain were not 
significantly associated with brain age, suggesting an alternative driving factor not encompassed 
by these variables. One aspect to consider is that total duration of pain and current pain level may 
be imperfect quantifiers of a patient’s trajectory with CLBP. Not only is it possible for pain 
intensity to change over time, the duration in which a patient experiences higher levels of pain may 
also be significant factor for the activation and possible enhanced response of various pain-related 
brain regions (Flor et al.; Wand et al., 2011). Previous literature has also suggested that both normal 
and pathologic structural brain changes themselves may contribute toward a patient’s experience 
of CLBP due to impairment of descending inhibition, implicating a bi-directional relationship 
between structural brain changes and chronic pain (J. Karp et al.). All these factors suggest that 
the trajectory of CLBP and its relationship to brain changes are more complex than may be 
characterized by measurements of only duration and pain at one instance (Flor et al.).  
Additionally, while BDI scores were taken as a measure of depressive symptoms in 
participants, most scores for CLBP participants were below the clinical threshold for major 
depressive disorder (BDI = 16). Although there is an extensive relationship between CLBP and 
depression, with overlap in their underlying neurobiology and impact on brain structure, our results 
suggest that there are also significant effects of CLBP on brain structure in the absence of Major 
 85 
Depressive Disorder (Gerhart et al.; Hung et al.; J. F. Karp et al.). However, two participants 
excluded as outliers had BDI scores of 17 and 19, with brain ages 15 and 21 years older than their 
chronological ages, respectively. A general positive trend between BDI scores in the major 
depressive disorder levels and greater brain aging in CLBP patients is suggested by the few 
participants which meet the clinical BDI threshold in the present study; however, further 
investigation of CLBP patients with major depressive disorder would be needed to draw a more 
definitive conclusion regarding brain age.  
A recent study of chronic pain and the discrepancy between predicted brain age and actual 
age has shown significant differences between chronic pain patients and healthy participants 
(Cruz-Almeida et al., 2019). While our results are overall corroboratory, there are several key 
distinctions to note, aside from this study’s specific focus on CLBP. Our present study features a 
much younger patient cohort, with mean ages of 50 years, versus the previous study’s mean age 
of 70 years. In addition, we investigated a larger HC group (n = 32) versus the previous study’s 
sample size of 14 individuals without chronic pain. However, many of the additional parameters 
investigated by the previous study, including therapeutic interventions for pain, psychological 
function, and somatosensory function, were not available in the present participant cohort, and 
therefore may further modulate the relationship between predicted brain age and chronological age 
in this study.  
The main limitations of this study are the limited sample sizes for CLBP and HC 
participants, as well as its cross-sectional nature. Conclusions regarding trends in brain age would 
be strengthened by a longitudinal analysis with multiple instances of participant imaging to 
construct trajectories with the development and treatment of CLBP. Additional measures of both 
pain intensity and duration at multiple time points would also allow for more sophisticated 
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measures of a cumulative pain burden. A limitation of the brain age model used is its holistic mode 
of analysis of overall gray matter density. In addition, the training set of the brain age model was 
not specifically screened for CLBP status in its participants. Therefore, the predicted brain age is 
not generated against a healthy control population, but rather a general, mixed population. A 
potential direction of future investigation may be to delineate the contributions of specific brain 
regions to accelerated aging. 
In this study we have demonstrated that brain age prediction using a machine-learning 
based model shows accelerated brain aging in CLBP patients. This measure may serve as a future 
clinical tool in tracking and possibly predicting a patient’s trajectory in brain changes with CLBP 





6.0 Application of Brain Age: Increased Brain Age in Non-Remitters Compared To 
Remitters Following Open-Label Treatment Of Late-Life Depression 
This chapter is a modified version of the following manuscript that is currently in 
submission:  
Yu, G.Z.*, Karim, H.T.*, Ly, M., Andreescu, C., Karp, J.F., Butters, M.A., Reynolds, C.F. 
III., Aizenstein, H.J. Increased brain age in non-remitters compared to remitters following open-
label treatment of late-life depression. *co-first authors. 
 
This work was intended to support Aim 3 by applying the brain age prediction model in 
cohorts with age-related neuropsychiatric disorders. In this study, we investigated pre- to post-
treatment changes in brain age in a cohort of participants with late-life depression (LLD) who 
received 12 weeks of open-label venlafaxine. We demonstrated that non-remitters demonstrated a 
significant increase in brain age over the intervention period while remitters showed no significant 
change in brain age over the same period. My contributions to this study were: design, analyses, 
interpretation, drafting and revising the manuscript.  
6.1 Introduction 
Late life depression is a leading source of disability in older adults, occurring in up to 38% 
of the population [1]. In addition to being highly prevalent, the clinical trajectory of LLD is often 
complicated by increased time to treatment response and higher rates of treatment resistance [2, 
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3]. This results in worsened patient outcomes and increased risk for suicide, dementia, 
exacerbations of medical comorbidities, and overall mortality [4, 5]. The biological mechanisms 
linking LLD with these health consequences have previously been attributed to chronic stress and 
inflammatory hypotheses in which high systemic levels of glucocorticoids and pro-inflammatory 
cytokines mediate neurodegenerative changes in brain structure [6-8].  
In support of these hypotheses, many cross-sectional studies have established relationships 
between changes in brain structure with LLD and its treatment response. Compared to healthy 
controls, LLD individuals have lower grey matter volumes in regions contributing to cognitive 
performance [9-11]. Furthermore, severity of grey matter volume differences in LLD patients have 
been associated with LLD symptomatic severity, decreased cognitive function, and decreased 
likelihood of LLD remission after treatment [12, 13]. However, these previous investigations have 
mostly been cross-sectional, using brain structure as a predictor rather than a longitudinal measure 
of disease progression or improvement. Few studies have examined structural brain changes over 
the course of treatment. ECT studies have reported only scarce evidence for the reverse of this 
disease-structure relationship, with increases in grey matter volume reported after 
electroconvulsive therapy [14]. However, no volumetric differences were reported between 
remitters and non-remitters following antidepressant monotherapy [14-16].  
Given that the pathophysiology of LLD as explained by the chronic stress and 
inflammatory hypotheses has been likened to accelerated aging, and that aging-associated brain 
genetic profiles have been found to contribute to LLD vulnerability, we sought to investigate the 
relationship between longitudinal structural brain changes and treatment response in LLD using 
our previously developed brain age prediction model [17-19]. 
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Our brain age prediction model contextualizes whole brain structural information of a test 
cohort against structural information from a large healthy participant cohort spanning a wide range 
of ages (20 to 85) to generate a machine learning-based prediction of the test participant’s 
chronological age. In this way, discrepancies between actual chronological age and predicted brain 
age in test groups may indicate pathological disruption or acceleration of the aging process [20]. 
Past studies have also shown that other neuropsychiatric diseases, including traumatic brain injury, 
schizophrenia, and epilepsy, have been associated with increases in brain age [21-23]. In our 
previous work, we have demonstrated the capacity of our grey matter density-based brain age 
model in distinguishing between the various cognitive stages of Alzheimer’s disease given the 
pivotal connection between structural changes and disease progression [24].  
Given the potential for brain age prediction to provide insight into the nature of structural 
changes in LLD, we aimed to investigate whether changes in brain age differed between remitters 
and non-remitters to treatment in LLD patients. We investigated pre- to post-treatment changes in 
brain age in a cohort of LLD participants (N = 46) who received open-label treatment with 
venlafaxine. Change in brain age pre- and post-treatment was compared between remitters and 
non-remitters. To our knowledge, this is one of the first studies applying the brain age metric to 
LLD following treatment and also one of the first studies to utilize longitudinal changes in brain 
age in a clinical context. We hypothesized that non-remitters may show an increase in brain age 
(pre- to post-treatment) greater than remitters. We further hypothesized that the extent of 
symptomatic persistence in non-remitters would correlate with greater increases in brain age. 
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6.2 Methods 
6.2.1 Participants and Study Design 
As part of a treatment study of LLD (NCT00892047 and NCT01124188), we collected 
neuroimaging data, which has also been described elsewhere [25, 26]. Data was collected from 
January 2012 until June 2016. Participants were included if they were 55 years and older, met 
Diagnostic and Statistical Manual of Mental Disorders IV criteria of major depression, and had a 
Montgomery-Asberg Depression Rating Scale (MADRS) of at least 15 at baseline. Participants 
were excluded if they had a history of mania or psychosis, alcohol or substance abuse within last 
3 months, or dementia or neurodegenerative disease as well as conditions that affect mood or the 
brain (e.g., stroke, vasculitis, unstable hypertension etc.). All participants gave written informed 
consent. The study was approved by the University of Pittsburgh Institutional Review Board.  
Participants underwent an open-label phase of treatment with venlafaxine XR – a 
serotonin-norepinephrine reuptake inhibitor. During this phase, we collected neuroimaging data at 
five time points: pre-treatment, after a placebo lead-in, after a single dose of venlafaxine (37.5mg), 
a week after starting venlafaxine, and post-treatment (~12 weeks). Structural MRI scans were only 
collected at pre- and post-treatment therefore we will only discuss processing of this data.  
During the first 6 weeks, participants returned for weekly/biweekly visits and dosage as 
increased up to 150mg/day per severity and tolerability. Participants who were still symptomatic 
(i.e., MADRS > 10) by week 6, the dose was increased per protocol to 300mg/day. Remission was 
defined as MADRS<10 for at least two visits during course of treatment. Participants were treated 
for 12-14 weeks but protocol guidelines allowed for a longer trial (up to 24 weeks) to clarify 
remission status.  
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We recruited a total of 63 participants into our study: 1 did not meet criteria for major 
depression, 2 had metallic implants, and 1 did not fit in the scanner. A total of 59 participants were 
treated with open-label venlafaxine XR: 2 discontinued communication and 4 discontinued 
treatment due to side effects (n=2), worsening of symptoms (n=1), or other medical conditions not 
related to treatment (n=1). To be included in our analysis, a pre- and post-treatment MRI scan was 
need, however some participants were excluded due to: claustrophobia in MR scanner after one 
scan (n=1), discomfort in MR scanner after one scan (n=1), continued treatment but refused 
follow-up imaging after second scan (n=1) or fourth scan (n=1). This resulted in a sum total of 49 
participants who completed treatment and MR scanning and who were included in our analysis.  
We also collected following data: demographic (age, sex, education, race), recurrent/single 
episode depression, and cumulative illness rating scale for geriatrics (CIRSG).  
 
6.2.2 MRI Data Acquisition 
Scanning was conducted at the University of Pittsburgh Medical Center on a 3T Siemens 
Trio TIM scanner (Munich, Germany). Structural MRI scans were collected at pre-treatment and 
post-treatment visits, while functional imaging scans (not described here) were collected at each 
visit. We collected an axial, whole brain 3D magnetization prepared rapid gradient echo 
(MPRAGE) was collected with repetition time (TR)=2300ms, echo time (TE)=3.43ms, flip angle 
(FA)=9 degrees, inversion time (TI)=900ms, field of view (FOV)=256x224, 176 slices, 1mm 
isotropic resolution and with GeneRalized Autocalibrating Partial Parallel Acquisition (GRAPPA) 
factor=2. An axial, whole brain 2D fluid attenuated inversion recovery (FLAIR) was collected 
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with TR=9160ms, TE=90ms, FA=150 degrees, TI=2500ms, FOV=256x212, 48 slices, and 1x1x3 
mm resolution. 
6.2.3 Structural Processing 
Processing was conducted using statistical parametric mapping (SPM12 
https://www.fil.ion.ucl.ac.uk/spm/software/spm12/) in MatLab (2016b, The MathWorks, Natick). 
Interpolation was done with 4th degree B-spline interpolation and normalized mutual information 
similarity metric was used for coregistration between different image types. The FLAIR was 
coregistered to the MPRAGE, and both were then input into a multispectral segmentation which 
bias corrects the images and segments them into gray matter, white matter, cerebrospinal fluid, 
skull, soft-tissue, and air [27]. Due to high white matter hyperintensity burden the number of 
Gaussians used to identify white matter was set to two to improve identification of gray and white 
matter [28]. The gray and white matter maps are input into a process to generate a study specific 
template for estimation of gray matter density.  
We used DARTEL (Diffeomorphic Anatomical Registration using Exponentiated Lie 
Algebra) to generate study specific gray and white matter templates – we conducted a specialized 
pipeline for longitudinal data analysis [29, 30]. DARTEL uses an iterative process of averages 
templates and coregistration to improve normalization to a standard anatomical space within a 
study. We leveraged longitudinal data by first generating a gray and white matter template for each 
participant using the pre- and post-treatment MRI. Those templates are then used to generate study-
specific templates of the gray and white matter. We can then multiply the Jacobian of the 
transformations to this study-specific template space to generate a gray matter density image [29]. 
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The gray matter density images were smoothed using a Gaussian kernel of full-width at half-
maximum of 6mm.  
6.2.4 Brain Age Estimation 
We have previously developed a brain age estimation algorithm for late-life populations 
[24]. Briefly this used the Pattern Recognition for Neuroimaging Toolbox (PRoNTo) to predict 
chronological age using gray matter density and machine learning [31]. Whole brain, voxel-wise 
grey matter densities were mean-centered and used to calculate a similarity matrix kernel (dot 
product), which was input into a Gaussian Processes Regression model with the similarity matrix 
as the independent variable and chronologic age as the dependent variable. The training set (n=757 
individuals) and inclusion criteria have been described previously [24]. Our current dataset was 
not a part of the training of this model. We then used this previously validated model to estimate 
brain age per time point in the 49 participants who were included in our analysis.  
6.2.5 Statistical Analysis 
All statistical analyses were performed in JMP Pro 14.1.0 (SAS Institute Inc., 2019). Three 
outliers were identified and removed on the basis of having change in brain age or MADRS score 
greater than 1.5 interquartile range above the third quartile (for a final cohort size of N = 46). 
Paired t-tests were used to compare pre- and post-treatment brain ages for the entire cohort 
followed by remitters and non-remitters separately. Multivariable regression modeling was used 
to determine the effect of remission status on change in brain age while adjusting for chronological 
age, sex, race, education, disease burden (CIRSG), and pre-treatment depression severity 
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(MADRS). This was also performed for all LLD non-remitters to determine the effect of change 
in brain age on change in depression severity (MADRS). As an additional exploratory analysis, 




Table 11 shows demographic and clinical information for both remitters and non-remitters. 
Non-remitters had lower pre- and post-treatment brain age as compared to remitters (t(44)=2.44, 
p=0.019 and t(44)=2.19, p=0.034 respectively). There were no differences in chronological age, 
sex, race, education, depression type (recurrent/single episode), cumulative illness burden 
(CIRSG), or pre-treatment depression severity (MADRS). As expected, remitters have a lower 
post-treatment MADRS.  
We found no change between pre- and post-treatment in brain age when we looked at the 
entire sample (t(45)=1.6, p=0.123, mean difference 0.09 and standard error of difference 0.06). 
However, we found that while remitters show no change in brain age pre- to post-treatment 
(t(23)=-0.5, p=0.602, mean difference -0.04 and standard error of difference 0.08), non-remitters 
showed an increase in brain age from pre- to post-treatment (t(21)=2.9, p<0.01, mean difference 
0.23 and standard error of difference 0.08) (see figure 12). A change in 0.23 years corresponds to 
approximately 11.96 weeks, the approximate duration between pre- and post-treatment MRI scans.  
We found that the change in brain age was associated with remission status and 
chronological age, but not sex, race, education, cumulative illness burden (CIRSG), and pre-
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treatment depression severity (MADRS) (F(7, 37)=2.45, p=0.036, r2=0.32) (see table 12). 
Individuals with the lowest improvement in depression severity following treatment had the largest 
increases in brain age (see figure 13).  
In addition, there was a strong association between change in brain age and change in 
depression severity (MADRS) for non-remitters (F(6, 14)=2.51, p=0.073, r2=0.52) (see table 13). 
Non-remitted individuals with less improvement in depression severity following treatment had 
larger increases in brain age. 
There was also a strong moderating effect of baseline depression severity on the 
relationship between age and baseline brain age for all participants (F(3,42)=3.20, p=0.033). The 
interaction effect between baseline depression severity and age was trending on significance as 
shown in table 14. 
 
Table 11. Demographic and clinical differences between remitters and non-remitters. 
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Table 12. Association between change in brain age and remission status adjusting for pre-treatment 
chronological age, sex, race, education, cumulative illness burden. 
 
Table 13.Association between change in depression severity (MADRS) for non-remitters and change in brain 




Table 14. Association between baseline brain age and participant chronological age, baseline depression 
severity (pre-MADRS), and their interaction effect. 
 
Figure 12. Change in brain age in remitters (red, square) and non-remitters (blue, triangle).  
Median and standard errors plotted as well as each individual participant’s change.  
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Figure 13. Association between change in depression severity (pre- minus post-treatment MADRS) and 
change in brain age (post- minus pre-treatment). 
Note that positive values in ∆ MADRS indicate improvement of depression severity while negative values in ∆ 
brain age indicate increased brain age from pre- to post-treatment. All participants (including remitters are 
shown). 
6.4 Discussion 
To our knowledge, this is the first study applying brain age prediction to LLD. In this study, 
brain age prediction was applied pre- and post- venlafaxine treatment in LLD patients. Our results 
showed that non-remitters demonstrated a significant increase in brain age over the intervention 
period while remitters showed no significant change in brain age over the same period. We found 
that change in brain age was significantly associated with remission status even after adjusting for 
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demographic and clinical features. For non-remitters, less improvement in depression severity 
(MADRS) was associated with larger increases in brain age.   
As previous literature has established a connection between regional grey matter atrophy 
and LLD, our results suggest that there may be subacute processes affecting brain structure on the 
same timescale as remission over the 12-week period of intervention [32-38]. The mean difference 
in brain age for non-remitters was approximately 0.23 years, or ~12 weeks older (matching the 
intervention period), while there was not a statistically significant change in remitters.  
One manner of interpretation is that LLD patients experience brain aging at the same rate 
as chronological aging, which in perspective with our previous experience with our brain age 
model, is a pathologically accelerated rate compared to the healthy population. The remitted group, 
in comparison, would have brains that have not appeared to have aged, as the intervention period 
would be too short to detect significant changes associated with normal aging.  
An alternative interpretation is that the non-remitted group experienced a rate of brain 
aging closer to normal, while the remitted group actually experienced a pause in brain aging (due 
to their brain ages having no significant change over the 12-week intervention period). This may 
be representative of a recovery respite from gray matter atrophy associated with LLD pathology 
(and in this case, normal aging as well), and therefore appear relatively younger as a result of 
remission. Current study design and data analysis does not allow us to distinguish between these 
interpretations.  
Both interpretations are suggestive of different processes in the context of LLD. 
Degenerative structural changes have been well documented and even associated with disease 
severity, with many past studies demonstrating lower gray matter volumes in LLD individuals 
compared to healthy controls, and even LLD non-remitters against remitters [32-38].  
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However, a 4-year study using serial MR imaging showed that the longitudinal increases 
in grey and white matter lesion sizes of LLD individuals did not differ significantly from the 
trajectory seen in normal aging, albeit being larger in size at baseline [39]. Whether the trajectory 
observed belonged to remitted or non-remitted individuals is unclear, however, as the authors note 
that remission status and symptomatic improvement were not followed in a controlled trial 
environment.  
Another longitudinal study which evaluated hippocampal volume at multiple time points 
after electroconvulsive therapy showed a transient increase in volume one week after treatment 
which normalized to baseline levels at 6 months post-treatment with no coevolution against 
symptomatic improvement [40]. It is also possible that our remitted group results are following a 
similar trend in which increases in gray matter volume are translated into apparently arrested brain 
aging which may not persist over a longer time course, for which a longer observation interval 
would be required to confirm. Potential mechanisms for these structural changes include increased 
neurogenesis in the dentate gyrus, increased neurotrophic factors such as brain-derived 
neurotrophic factor: BDNF), and reduction of stress/allostatic burden which in turn reduces HPA-
axis-mediated suppression of neurogenesis.  
While the association between treatment response and change in brain age seen in the linear 
modeling is expected given the increase in brain age exclusive to the non-remitted group, there 
was still a statistically significant improvement in disease severity (MADRS) for non-remitters 
(t(21) = -5.51, mean difference = -7.55, standard error of the mean difference = 1.37, p < 0.0001). 
Not only did individual non-remitters differ in the lessening of their disease severity, but there was 
a strong association between the extent of this change and the change in their individual brain age, 
suggesting that brain age may also serve as a quantitative measure of improvement. An alternative 
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interpretation is that the extent of remaining LLD pathology for those patients could be explained 
by the increase in brain age experienced by each individual. 
In all, these results suggest there is significant potential in the utility of brain age prediction 
model when applied to LLD, and that structural brain changes seen in LLD may indeed be 
contextualized by the aging process. Brain age prediction is in some ways a simplification or 
aggregate measure of overall morphometric brain changes and loses the regional specificity of 
many previous studies. However, its quantitative nature provides a longitudinal metric that may 
help consolidate morphometric brain changes that are sensitive to even a 12-week period. Our 
results also offer additional supporting evidence for potentially significant morphometric changes 
accompanying symptomatic improvement in LLD, although a longer follow-up period would help 
confirm that these changes are not transient.  
6.4.1 Limitations 
There are several limitations and areas for future improvement. In our study, the remitters 
and non-remitters were not matched for pre-treatment brain age. As mentioned earlier, 
interpretation of our results, while showing significant relative differences between remitters and 
non-remitters, lacks an absolute comparison which longitudinal brain age measurements of a 
healthy cohort would provide. Our brain age model was trained on cross-sectional measurements 
of a healthy population and shares this limitation. 
Generalizability of our results and utilization of brain age differences for prediction of 
disease remission are also limited by the small sample size of this treatment trial. Our study is an 
open-label trial and it is unclear whether these changes would be present in a randomized placebo-
controlled study. It is unclear whether this generalizes to mid-life samples or is characteristic of 
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late-life depression. Potential future improvements may also include intervention with other 
antidepressant interventions and an extended period of evaluation or follow-up imaging. Other 
factors potentially contributing to changes in disease severity and brain age not considered in this 
study may include neurocognitive testing and functional MR imaging, which have previously been 
investigated elsewhere in the current cohort [3, 25, 26, 41]. 
6.4.2 Conclusions 
This study demonstrated the potential utility of brain age prediction in resolving the 
differences in structural trajectories between remitted and non-remitted LLD individuals and 
shows a strong relationship between the extent of persisting symptomology and brain age changes 
in non-remitted individuals. This marker could help us understand the potential long-term 
consequences of extended periods of depression. Future studies should investigate whether brain 
age predicts incident depression; whether depression history (i.e., number of episodes and extent 
of symptoms) predicts greater brain age; and whether these changes indicate long-term changes 
(i.e., brain age continues to increase in non-remitters and is slowed to the rate of remitters in never-
depressed individuals). 
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7.0 Application of Brain Age: Brain Aging Associated With Greater Worry And 
Rumination In Late-Life 
This chapter is a modified version of the following manuscript that is currently in 
submission:  
Karim, H.T., Ly, M., Yu, G., Khan, F., Krafty, R., Tudorascu, D.L., Aizenstein, H.J., Gross, 
J., Andreescu, C. Brain aging associated with greater worry and rumination in late life.  
 
This work was intended to support Aim 3 by applying the brain age prediction model in 
cohorts with age-related neuropsychiatric disorders. In this study, we demonstrated that worry and 
rumination may drive accelerated aging in late-life generalized anxiety (LLGAD). My 
contributions to this study were: analyses, interpretation, and drafting and revising the manuscript.  
7.1 Introduction 
“Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” Mark Twain 
 
In the last decade, several studies have reported an independent effect of anxiety on aging. 
Clinically, anxiety and its disorders have been described as risk factors for multiple age-related 
medical conditions 1-4.  More specifically, pathologic worry in particular is associated with the 
development of coronary heart disease 3 and a higher burden of anxiety symptoms was associated 
prospectively with increased risk for incident stroke, independent of other risk factors (including 
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depression) 4. In the Nurses’ Health Study, a 4-year longitudinal study of community-dwelling 
older women (N=16,351), higher midlife anxiety was related to worse later-life overall cognition 
and verbal memory5. Chronic anxiety has been also associated with a higher beta amyloid burden6, 
as well as with a moderating effect of the impact of beta amyloid on cognitive decline 7,8. In a 2-
year observational study, older adults with mildly elevated worry symptoms performed worse on 
measures of visual learning and memory than older adults with no/minimal worry symptoms9. 
Multiple animal studies reported impaired neurogenesis in anxiety 10, and several human studies 
described brain structural changes associated with anxiety in midlife (e.g. reduced hippocampal 
volumes and reduced gray matter density in the amygdala and hippocampus11). Our previous 
reports in a geriatric anxiety sample describe structural grey matter changes such as thinning of 
the orbital frontal cortex and rostral anterior cingulate cortex in late-life Generalized Anxiety 
Disorder (GAD)12 and a potential effect of cerebrovascular burden in impairing emotion regulation 
in late-life GAD 13.  
All these studies indicate that anxiety and/or worry contribute to accelerated aging. The 
putative mechanisms enlist molecular aging markers [e.g. shorten telomere 14] and increased 
stress-response [chronic inflammatory stress, increased HPA activity and excessive autonomic 
responses 15-17]. However, research in this area is still in early stages and the pathway linking 
anxiety or worry with brain aging remains unclear.  
Most of the studies available regarding the potential effect of late-life anxiety in accelerated 
aging use heterogenous and often non-specific measures for anxiety. Anxiety and its disorders 
encompass multiple clinical constructs such as worry, rumination, somatization [ref] and it is 
highly comorbid with both depression and neuroticism [refs]. It is thus more difficult to detangle 
the specific effect of various phenotypes on accelerated aging 18. Additionally, the highly 
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heterogenous changes that occur in aging make it difficult to interpret various correlation studies 
that point toward an association between anxiety and aging.  
Brain age prediction is a machine learning method that estimates chronological age from 
brain scans. Thus, brain age may indicate a potential discrepancy between biological and 
chronological age, suggesting that pathological neuroprogression (combination of 
neurodegeneration, neurotoxicity and lowered neuroplasticity) is associated with accelerated aging 
15.  These models have been used recently to demonstrate the associated of increased brain age 
with cognitive impairment, Alzheimer’s disease, schizophrenia or traumatic brain injury (refs). In 
a previous report 19, our group has described a machine learning method for estimating brain age 
from neuroimaging scans while accounting for amyloid status. Our brain age prediction model 
contextualizes whole brain structural information of a test cohort against structural information 
from a large healthy participant cohort spanning a wide range of ages (20-85) to generate a machine 
learning-based prediction of the test participant’s chronological age. In this way, discrepancies 
between actual chronological age and predicted brain age in test groups may indicate pathological 
disruption or acceleration of the aging process. We reported that our model was able to delineate 
significant differences in the brain age relative to chronological age between cognitively normal 
individuals with and without amyloid beta deposition in the brain 19. 
In the current study, we aimed to test if any of the multiple anxiety phenotypes (worry, 
global anxiety, rumination) as well as their more frequent comorbidities (depression severity, 
neuroticism) are predictive of brain aging. Given the hypothesis regarding the role of increased 
stress response we also included the Perceived Stress Questionnaire20 in the model. Also, as our 
previous reports regarding emotion regulation deficits in late-life anxiety 13,21,22, we also included 
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in the current model the Emotion Regulation Questionnaire (ERQ), a self-report measure of two 
emotion regulation strategies (cognitive reappraisal and expressive suppression) 23.  
7.2 Methods 
7.2.1 Participants and Study Design 
We recruited participants (n=78) who were 50 years and older and were recruited in along 
the spectrum of worry, such that worry was normally distributed. We recruited individuals with 
and without anxiety (generalized anxiety disorder, panic disorder, social phobia, etc.) and/or mood 
disorders (e.g., major depressive disorder, persistent depressive disorder, or unspecified depressive 
disorder). Participants were excluded if they were: diagnosed with autism spectrum disorders, 
intellectual development disorder, or any form of psychosis or bipolar disorder. Other exclusion 
criteria were: a diagnosis of major neurocognitive disorder (e.g., dementia), a 3MS (modified mini-
mental) score < 84, a diagnosis of personality disorder, have suicide risk, use of antidepressants 
within the last five to fourteen days (participants were allowed to washout), history of drug/alcohol 
abuse within last six months, use of high doses of benzodiazepines (greater than equivalent to 2mg 
of lorazepam), uncorrected vision problems to would preclude neuropsychiatric testing, below 6th 
grade level of reading, clinical diagnosis of cerebrovascular accident or Multiple Sclerosis or 
vasculitis or significant head trauma, ferromagnetic objects in body, claustrophobia, or too large 
to fit in MR scanner.  
When appropriate, participants underwent an adequate washout on antidepressants 
determined by the primary psychiatrist on the study (CA). For fluoxetine, the washout interval was 
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6 weeks. Participants who are prescribed low dose psychotropics for pain, sleep disturbances, 
and/or medical conditions were allowed to continue them in most circumstances. The following 
common antidepressants were allowed at particular doses due to medical reasons: amitriptyline 
(50mg/day), doxepin (50mg/day), trazodone (100mg/day), and imipramine (50mg/day). 
Participants were recruited from the Pittsburgh area via Pitt+Me (website resource from the 
university), in-person recommendations, flyers around the city, and radio/television 
announcements. This study was approved by the University of Pittsburgh Institutional Review 
Board. All participants gave written informed consent prior to participating in the study.  
7.2.2 Assessments  
Along with demographic information (age, sex, race, and education), we assessed the 
following: worry (PSWQ, Penn State Worry Questionnaire), overall anxiety (HARS, Hamilton 
Anxiety Rating Scale), depression (MADRS, Montgomery-Asberg Depression Rating Scale), 
rumination subscale (RSQ, Response Style Questionnaire), neuroticism subscale (FFI, Five-Factor 
Inventory), perceived stress (PSS, Cohen’s Perceived Stress Scale), and the habitual use of 
cognitive reappraisal and suppression subscale (ERQ, Emotion Regulation Questionnaire). We 
also collected data on illness severity (CIRS-G, cumulative illness rating scale for geriatrics).  
7.2.3  MRI Data Acquisition 
MRI scans were obtained at the MR Research Center of the University of Pittsburgh using 
a 3T Siemens MAGNETOM Prisma scanner and a 32-channel head coil. A sagittal, whole-brain 
T1-weighted magnetization prepared rapid gradient echo (MPRAGE) was collected with repetition 
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time (TR)=2400ms, echo time (TE)=2.22ms, flip angle (FA)=8deg, field of view (FOV)=320x300 
with 208 slices, 0.8mm3 isotropic resolution, 0.4mm slice gap, and GeneRalized Autocalibrating 
Partial Parallel Acquisition (GRAPPA) with acceleration factor of 2 (total time 6.63min). A 
sagittal, whole-brain T2-weighted Sampling Perfection with Application optimized Contrasts 
using different flip angle Evolution (SPACE) was also collected with TR=3200ms, TE=563ms, 
FA=120deg, FOV=320x300 with 208 slices, 0.8mm3 isotropic resolution, no slice gap, and 
GRAPPA with acceleration factor of 2 (total time 5.95min). An axial, whole-brain T2-weighted 
Fluid Attenuated Inversion Recovery (FLAIR) was also collected with TR=10,000ms, TE=91ms, 
FA=135deg, FOV=320x320 with 104 slices, 0.8mm x 0.8mm x 1.6mm resolution, no slice gap, 
and GRAPPA with acceleration factor of 2 (total time 5.95min). 
7.2.4 Structural Processing 
Processing was conducted in statistical parametric mapping toolbox (SPM12)24 in MatLab 
2018b (MathWorks, Natick, MA). All interpolation was done with a 4th degree B-spline and the 
similarity metric used for coregistration between different image types was normalized mutual 
information. The T2-SPACE and FLAIR were first independently coregistered to the MPRAGE. 
All three were input into a multispectral segmentation which bias corrects each image and 
segments them into gray matter, white matter, cerebrospinal fluid, skull, soft-tissue, and air25. Due 
to high white matter hyperintensity, we adjusted the number of Gaussians used to identify white 
matter to two to improve identification of gray and white matter26. The gray and white matter maps 
are inputs into a process to generate a study-specific template to estimate gray matter density.  
We used DARTEL (Diffeomorphic Anatomical Registration using Exponentiated Lie 
Algebra) to generate study-specific templates27. DARTEL uses an iterative process of averages 
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across participants and iterative coregistration to improve normalization to a standard anatomical 
space. Once a study-specific template is generated (an iterative average across participants), each 
image is normalized and then transformed into a gray matter density image by multiplying the 
Jacobian of the transformations27. The gray matter density images were smoothed using a Gaussian 
kernel of full-width at half-maximum of 6mm. These gray matter density images are input into the 
brain age estimation model.  
7.2.5 Brain Age Estimation 
We have previously validated a brain age estimation algorithm that predicts chronological 
age with gray matter density maps19 using the Pattern Recognition for Neuroimaging Toolbox 
(PRoNTo)28. Whole brain, voxel-wise gray matter densities were mean-centered and used to 
calculate a similarity matrix kernel (dot product) that was input into a Gaussian processes 
regression to predict chronological age. The training set, which includes 757 adult MRI’s of 
individuals without any psychiatric or neurological disorder as well as Alzheimer’s pathology as 
measured by positron emission tomography, has been previously described19. The current study’s 
participants were not part of the training set. Using this pre-trained model, we can estimate the 
brain age of each participant in the current study.  
7.2.6 Statistical Analysis 
We conducted a linear regression analysis in SPSS 26 (IBM, Armonk, NY). We used brain 
age as the outcome and the following as independent predictors: chronological age, sex, education 
(years), worry (PSWQ), anxiety (HARS), depression severity (MADRS), rumination (RSQ), 
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neuroticism (FFI-Neuroticism), reappraisal (ERQ, reappraisal subscale), suppression (ERQ, 
suppression subscale), and stress (PSS). The models conducted all had variance inflation factor 
(VIF) below 5, showed normally distributed standardized residuals (based on a histogram and QQ-
plot), and did not violate the assumption of homoscedasticity.  
A total of 69 participants (88.5%) had all data available, however there were missing values 
for: HARS (2 lost questionnaires), MADRS (3 not collected, 2 lost questionnaire), RSQ (1 
participant error, 1 not collected), FFI (2 refused, 4 participant error), ERQ (1 refused, 3 participant 
error), and PSS (1 refused, 3 participant error). We conducted multiple imputations analysis29,30 
(500 imputations) to impute missing values using the Markov Chain Monte Carlo method31 and 
fully conditional specification with linear regression since our values were missing at random and 
showed no structure in the way the data were missing.  
Every variable used in the regression as well as the outcome (brain age) was used in the 
model, as this has been shown to improve the imputation and is not ‘self-fulfilling prophecy,’ but 
rather “replays the strength of associations between predictors and outcomes present in the 
complete cases, to enable valid analyses32.” All variables were constrained to their appropriate 
values (e.g., HARS ranges from 0 to 56 thus values may not be imputed outside this range). We 
report both the imputed pooled results as well as the estimates from the original model with missing 
data (n=68).  
Each variable was inspected for outliers and the following variables had some outliers: 
HARS (n=1), MADRS (n=4), RSQ (n=1), brain age (n=2), and reappraisal ERQ subscale (n=1). 
We conducted the regression with those participants removed (not shown) and found that the 
estimates did not differ from when they were included in the model.  
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7.3 Results 
We report the characteristics of the sample in table 1. Of note worry is normally distributed 
around a mean worry severity of 47.6. Racial demographics match that of the surrounding 
Pittsburgh area.  
We found that brain age was significantly associated with several factors that explained 
72% of the variance in brain age [F(11,57)=13.3, p<0.001, r2=0.72]. We found the following: (1) 
for every one chronological year participant’s brain age went up by approximately 0.57 years (~6.8 
months); (2) women were younger by ~3.4 years compared to men; and (3) for every one point 
greater on the RSQ, brain age was greater by 0.14 years (~1.7 months) (see table 2 and figure 1).  
However, after imputing values that were missing for 9 participants (see table 1), we 
reconducted our regression and found the following (pooled results): (1) for every one 
chronological year participant’s brain age went up by approximately 0.53 years (~6.4 months); (2) 
women were younger by ~4.1 years compared to men; (3) for every one point greater on the 
PSWQ, brain age was greater by 0.11 years (~1.3 months); (4) for every one point greater on the 
RSQ, brain age was greater by 0.11 years (~1.3 months); and (5) for every one point greater on 
the ERQ suppression scale, brain was lower by 0.17 years (~2.0 months). The imputed models 
explained 68 to 72% (range) of the variance in brain age across imputations (variance is not a 
pooled metric; thus, we report the range). We show associations between these factors in figure 1 





Table 15. Characteristics of the LLGAD sample 
-Means and standard deviations are reported unless otherwise noted  















Table 16. Regression model explaining variance in brain age using imputed data. 
-B indicate unstandardized coefficients. We also report 95% confidence intervals and indicate significant 




Our results indicate that worry and rumination drive the accelerated aging effect of anxiety 
in late-life. Surprisingly, there was no effect of perceived stress and the propensity to use 
suppression rather than reappraisal seems to have a protective effect on brain aging. 
Although sharing common phenomenological features (difficult to control repetitive 
thinking), worry and rumination have been usually described as two distinct symptoms, one 
(worry) usually associated with generalized anxiety and the other one (rumination) usually 
associated with depression33. Classically, rumination theories consider rumination is triggered by 
sad mood and it maintains depressive symptoms by promoting negative cognitive biases 34. 
Similarly, classic worry theoretical models such as Borkovec’s cognitive avoidance model, posit 
that worry serves a cognitive avoidance strategy that inhibits the emotional processing of highly 
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anxiogenic material 35. However, newer theories propose a transdiagnostic approach that 1) 
includes both worry and rumination under the umbrella of negative repetitive thoughts (NRT) and 
2) describe the detrimental effect of NRTs throughout multiple categorical diagnoses including 
major depression, GAD, Social Phobia, Bipolar disorder, Obsessive compulsive Disorder, Eating 
disorders and PTSD36,37. Several authors have proposed NRT as the core of anxiety-depression 
comorbidity38,39, while others emphasized the association of NRT with worse psychological, 
physical and cognitive health in older adults 40. 
Recently, NRTs have been “imported” in the aging and dementia field. Thus, in 2015, 
Marchant & Howard have advanced a model of Cognitive Debt that would involve certain 
symptoms/disorders actively depleting cognitive reserve and increase vulnerability to AD 41. Thus, 
there is building evidence that depression, anxiety, sleep disorders, neuroticism and PSTD increase 
risk for AD and the authors suggest that RNT are the process common to these factors which may 
drive the acquisition of Cognitive Debt through diverting cognitive and emotional resources to 
distressing thought processes41. The neurobiological signature of Cognitive Debt and AD might 
rely on the relationship between hippocampus, PFC and the amygdala, and the HPA stress 
response 41.  
Our results, that single out both worry and rumination as predictive of accelerated aging, 
would fit well in the overall model of NRTs as contributing to increased Cognitive Debt. These 
results also emphasize the need for preventative interventions targeting NRTs in older adults (e.g. 
mindful meditation, cognitive behavioral therapy or positive reappraisal therapy – a newer attempt 
to incorporate mindful meditation into cognitive therapy 42). 
Regarding the protective role of expressive suppression, a response-focused form of 
emotion regulation that seeks to prevent the outward expression of an already-generated emotion43, 
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several studies have indicated the positive association between expressive suppression and 
volumes of the anterior insula, dorsomedial PFC and dorsal ACC 44-47. Although there is data 
linking expressive suppression to anxious and depressive symptoms 23 as well as memory 
impairment48, we may cautiously interpret these results through the use-dependent brain plasticity 
theory 44,49 that posits a ‘use it or lose it’ approach. Thus, chronic preferential use of expressive 
suppression may maintain a higher volume in prefrontal brain regions counterbalancing thus the 
thinning effect of aging. An additional explanation involves the age group used in the current study 
– emotion regulation strategies effective in younger adults may become less effective with age50 
and although older adults report using cognitive reappraisal more than younger adults, it is possible 
that older adults may rely less on a resource-demanding strategy such as reappraisal and use 
simpler techniques such as distraction or suppression 51. 
Our study has several limitations: we do not have longitudinal data to follow-up on the 
effect of the predictive factors described above, we do not have any other biological markers of 
aging to corroborate the current results (e.g. inflammatory cytokines, cortisol levels, cerebral beta-
amyloid burden). Most participants had mild if any depressive symptoms, thus we cannot make 
inferences about the effect of clinical depression on accelerated aging. 
In conclusion, we present novel data suggesting a deleterious effect on aging of both worry 
and rumination in older adults as well as a potential protective effect of using expressive 
suppression. There results also emphasize the role of preventative interventions in reducing 
accelerated aging by targeting modifiable factors such as worry and rumination in late-life. 
 116 
8.0 Summary and Discussion 
 
The work of this dissertation mainly involves exploring the role of brain reserve and 
cognitive reserve in neuropsychiatric pathologies and then utilizing brain age prediction as a means 
of quantifying and exploring relationships between brain reserve and pathologic progression or 
severity. Although currently we have a variety of neuropsychiatric batteries and clinical 
biomarkers for various diseases, there is still significant variation between individuals which 
cannot be explained for by existing biomarkers alone. This was demonstrated in the work involving 
LLD such that LLD patients and healthy controls did not have significant differences in the rate of 
their cognitive decline, but LLD patients had decreased baseline levels of cognitive function which 
are thought to represent the diminished brain or cognitive reserve associated with disease burden. 
This was also demonstrated in functional imaging of participants with subjective cognitive decline, 
where higher educated individuals (representing individuals with increased cognitive reserve) had 
significantly different patterns of neural activation when faced with a memory encoding task 
compared to less educated individuals, suggesting that cognitive reserve is a significant factor in 
differentiating compensatory mechanisms of neural activation in light of age-related cognitive 
decline. Both of these studies demonstrate different aspects of significance for cognitive reserve. 
 
In light of these conclusions and the overarching potential for cognitive and brain reserve 
to contribute toward clinical understanding of neuropsychiatric disease progression, we developed 
a novel model of brain age prediction through machine learning-based training on an amyloid 
negative healthy population. Not only did this novel model result in significantly improved 
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performance in delineating between different cognitive stages of AD progression compared to 
previously published models, it also provided an opportunity for more sophisticated analysis of 
pathologic contexts relevant to brain reserve.  
 
As such, we applied our brain age prediction model to settings of LLGAD, CLBP, and 
depression. In these works, we demonstrated that there is significant capacity for brain age 
prediction to quantify changes in brain reserve associated with these pathologies and various 
pathologic features. In LLGAD, we found that increased brain age (representing diminished brain 
reserve) was associated with increased worry and rumination patient characteristics, while 
suppression, a defense mechanism of LLGAD, was associated with mitigation of the effects of 
increased brain age. In CLBP, we found that LBP patients had significantly increased trends of 
brain age versus chronological age compared against healthy participants, representative of 
accelerated brain aging that was independent from commonly utilized traits of CLBP such as pain 
duration and pain severity. Given the importance and implications of brain structural reserve in 
cognitive function and mood, brain age prediction offers a potential biomarker to track CLBP 
progression and increased risk for psychiatric comorbidities common to chronic pain such as 
depression. In depression we found that longitudinal measurement of brain reserve showed 
significant differences between disease remitters and non-remitters in a direct link between 
structural brain changes and successful reduction of symptomatic disease severity. As a predictive 
measure, brain age holds significant potential as a distinct measure for evaluation of antidepressant 
therapy efficacy as well as disease progression given its successful longitudinal application. 
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In all, brain age prediction remains a promising concept for the characterization and 
prediction of a wide range of pathological contexts. Brain age prediction also offers a holistic 
impression of the entire brain and its structural changes in which pre-determined regional analysis 
lacks. Given the significant variation which exists between the age-related structural changes in 
different individuals, fitting an individual’s structural imaging against a vast dataset of healthy 
individuals is a quantifiable measure which may identify key differences (as demonstrated) which 
may be missed by more localized analyses. Further refining of the model through adaptive training 
set selection and more extensive longitudinal data collection may not only improve its capacity for 
predicting disease progression and remission as well as offer additional information for clinical 
decision making. Of course, other future directions for brain age prediction studies include 




Aalami, O. O., Fang, T. D., Song, H. M., & Nacamuli, R. P. (2003). Physiological features of 
aging persons. Archives of Surgery, 138(10), 1068-1076. 
 
Aizenstein HJ, Baskys A, Boldrini M, et al. Vascular depression consensus report - a critical 
update. BMC Med 2016; 14(1): 161. 
 
Aldao A, Nolen-Hoeksema S, Schweizer S. Emotion-regulation strategies across 
psychopathology: A meta-analytic review. Clin Psychol Rev. 2010;30(2):217-237. 
 
Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. Int J 
Geriatr Psychiatry 2011; 26(11): 1109-18. 
 
Amariglio, R.E., Becker, J.A., Carmasin, J., Wadsworth, L.P., Lorius, N., Sullivan, C., Maye, 
J.E., Gidicsin, C., Pepin, L.C., Sperling, R.A., Johnson, K.A., Rentz, D.M., 2012. Subjective 
cognitive complaints and amyloid burden in cognitively normal older individuals. 
Neuropsychologia 50(12), 2880-2886.  
 
Amieva H, Mokri H, Le Goff M, Meillon C, Jacqmin-Gadda H, Foubert-Samier A, et al. 
Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 
years of cognitive decline. Brain. 2014;137(Pt 4):1167-75. 
 
Andreescu C, Mennin D, Tudorascu D, et al. The many faces of anxiety-neurobiological 
correlates of anxiety phenotypes. Psychiatry Res. 2015;234(1):96-105. 
 
Andreescu C, Sheu LK, Tudorascu D, et al. Emotion reactivity and regulation in late-life 
generalized anxiety disorder: functional connectivity at baseline and post-treatment. Am J 
Geriatr Psychiatry. 2015;23(2):200-214. 
 
Andreescu C, Tudorascu D, Sheu LK, et al. Brain structural changes in late-life generalized 
anxiety disorder. Psychiatry Res. 2017;268:15-21. 
 
Andreescu C, Varon D. New research on anxiety disorders in the elderly and an update on 
evidence-based treatments. Curr Psychiatry Rep. 2015;17(7):595. 
 
Andreescu, C. and H. Aizenstein, MRI studies in late-life mood disorders. Curr Top Behav 
Neurosci, 2012. 11: p. 269-87. 
 
Andreescu, C., et al., Gray matter changes in late life depression--a structural MRI analysis. 
Neuropsychopharmacology, 2008. 33(11): p. 2566-72. 
 
 120 
Andreescu, C., et al., Resting state functional connectivity and treatment response in late-life 
depression. Psychiatry Res, 2013. 214(3): p. 313-21. 
 
Apkarian, A.V., Y. Sosa, S. Sonty, R.M. Levy, R.N. Harden, T.B. Parrish, and D.R. Gitelman, 
Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J 
Neurosci, 2004. 24(46): p. 10410-5. 
Asami, T., et al., Longitudinal loss of gray matter volume in patients with first-episode 
schizophrenia: DARTEL automated analysis and ROI validation. Neuroimage, 2012. 59(2): p. 
986-996. 
 
Ashburner, J. and K.J. Friston, Unified segmentation. Neuroimage, 2005. 26(3): p. 839-851. 
 
Ashburner, J., A fast diffeomorphic image registration algorithm. Neuroimage, 2007. 38(1): p. 
95-113. 
 
Baldwin, R.C., et al., The prognostic significance of abnormalities seen on magnetic resonance 
imaging in late life depression: clinical outcome, mortality and progression to dementia at three 
years. International journal of geriatric psychiatry, 2000. 15(12): p. 1097-1104. 
Becker, J.T., Boller, F., Saxton, J., McGonigle-Gibson, K.L., 1987. Normal rates of forgetting of 
verbal and non-verbal material in Alzheimer's disease. Cortex 23(1), 59-72. 
Beheshti, I., Maikusa, N., Matsuda, H., 2018. The association between "Brain-Age Score" (BAS) 
and traditional neuropsychological screening tools in Alzheimer's disease. Brain Behav 8(8), 
e01020. 
 
Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas 
2014; 79(2): 184-90. 
 
Bennett, I. J., & Madden, D. J. (2014). Disconnected aging: cerebral white matter integrity and 
age-related differences in cognition. Neuroscience, 276, 187-205. 
 
Bhalla RK, Butters MA, Becker JT, et al. Patterns of mild cognitive impairment after treatment 
of depression in the elderly. Am J Geriatr Psychiatry 2009; 17(4): 308-16. 
 
Bhalla RK, Butters MA, Mulsant BH, et al. Persistence of neuropsychologic deficits in the 
remitted state of late-life depression. Am J Geriatr Psychiatry 2006; 14(5): 419-27. 
 
Blalock, E. M., Chen, K. C., Sharrow, K., Herman, J. P., Porter, N. M., Foster, T. C., & 
Landfield, P. W. (2003). Gene microarrays in hippocampal aging: statistical profiling identifies 
novel processes correlated with cognitive impairment. Journal of Neuroscience, 23(9), 3807-
3819. 
 
Bland, J.M., Altman, D.G., 2011. Correlation in restricted ranges of data. BMJ 342, d556. 
 
 121 
Borkovec TD. The nature, functions, and origins of worry. . In: Tallis GDF, ed. Worrying: 
Perspectives on theory, assessment, and treatment. Sussex, England: Wiley & Sons; 1994. 
 
Boss, G. R., & Seegmiller, J. E. (1981). Age-related physiological changes and their clinical 
significance. Western Journal of Medicine, 135(6), 434. 
Bouckaert, F., et al., Grey matter volume increase following electroconvulsive therapy in 
patients with late life depression: a longitudinal MRI study. Journal of psychiatry & 
neuroscience: JPN, 2016. 41(2): p. 105. 
 
Bouckaert, F., et al., Relationship between hippocampal volume, serum BDNF, and depression 
severity following electroconvulsive therapy in late-life depression. Neuropsychopharmacology, 
2016. 41(11): p. 2741. 
Broadbent, D.E., Cooper, P.F., FitzGerald, P., Parkes, K.R., 1982. The Cognitive Failures 
Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21 (Pt 1), 1-16.  
Buchbinder, R., M. van Tulder, B. Öberg, L.M. Costa, A. Woolf, et al., Low back pain: a call for 
action. The Lancet, 2018. 391(10137): p. 2384-2388. 
 
Buckalew, N., M.W. Haut, H. Aizenstein, L. Morrow, S. Perera, H. Kuwabara, and D.K.J.P.M. 
Weiner, Differences in brain structure and function in older adults with self-reported disabling 
and nondisabling chronic low back pain. 2010. 11(8): p. 1183-1197. 
 
Buckalew, N., M.W. Haut, L. Morrow, and D. Weiner, Chronic pain is associated with brain 
volume loss in older adults: preliminary evidence. Pain Med, 2008. 9(2): p. 240-8. 
Buckley, R.F., Hanseeuw, B., Schultz, A.P., Vannini, P., Aghjayan, S.L., Properzi, M.J., 
Jackson, J.D., Mormino, E.C., Rentz, D.M., Sperling, R.A., Johnson, K.A., Amariglio, R.E., 
2017. Region-Specific Association of Subjective Cognitive Decline With Tauopathy 
Independent of Global beta-Amyloid Burden. JAMA Neurol 74(12), 1455-1463.  
Butters MA, Whyte EM, Nebes RD, et al. The nature and determinants of neuropsychological 
functioning in late-life depression. Arch Gen Psychiatry 2004; 61(6): 587-95. 
Butters, M.A., et al., Pathways linking late-life depression to persistent cognitive impairment and 
dementia. Dialogues in clinical neuroscience, 2008. 10(3): p. 345. 
 
Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011; 7(6): 
323-31. 
 
Cabeza R, Anderson ND, Locantore JK, McIntosh AR. Aging gracefully: compensatory brain 
activity in high-performing older adults. NeuroImage. 2002;17:1394–402. 
 
Chang, C.-C., et al., Reduction of dorsolateral prefrontal cortex gray matter in late-life 
depression. Psychiatry Research: Neuroimaging, 2011. 193(1): p. 1-6. 
 
 122 
Chen, P.S., et al., White matter and subcortical gray matter lesion volume changes and late-life 
depression outcome: a 4-year magnetic resonance imaging study. International psychogeriatrics, 
2006. 18(3): p. 445-456. 
 
Classen J, Liepert J, Wise SP, Hallett M, Cohen LG. Rapid plasticity of human cortical 
movement representation induced by practice. J Neurophysiol. 1998;79(2):1117-1123. 
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. Journal of health 
and social behavior. 1983;24(4):385-396. 
Cohen, A.D., Mowrey, W., Weissfeld, L.A., Aizenstein, H.J., McDade, E., Mountz, J.M., Nebes, 
R.D., Saxton, J.A., Snitz, B., Dekosky, S., Williamson, J., Lopez, O.L., Price, J.C., Mathis, C.A., 
Klunk, W.E., 2013. Classification of amyloid-positivity in controls: comparison of visual read 
and quantitative approaches. Neuroimage 71, 207-215.  
Cohen, A.D., Weissfeld, L.A., Mathis, C.A., Klunk, W.E., De-Kosky, S.T., 2009. Amyloid 
imaging in mild cognitive impairment subtypes. Ann Neurol 65(5), 557-568. 
Woods, R.P., Mazziotta, J.C., Cherry, S.R., 1993. MRI-PET registration with automated 
algorithm. J Comput Assist Tomogr 17(4), 536-546.  
Cohen, B.E., D. Edmondson, and I.M. Kronish, State of the art review: depression, stress, 
anxiety, and cardiovascular disease. American journal of hypertension, 2015. 28(11): p. 1295-
1302. 
 
Cole, J.H., Annus, T., Wilson, L.R., Remtulla, R., Hong, Y.T., Fryer, T.D., Acosta-Cabronero, J., 
Cardenas-Blanco, A., Smith, R., Menon, D.K., Zaman, S.H., Nestor, P.J., Holland, A.J., 2017. 
Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive 
decline. Neurobiol Aging 56, 41-49. 
 
Cole, J.H., et al., Prediction of brain age suggests accelerated atrophy after traumatic brain 
injury. Annals of neurology, 2015. 77(4): p. 571-581. 
 
Cole, J.H., Franke, K., 2017. Predicting Age Using Neuroimaging: Innovative Brain Ageing 
Biomarkers. Trends Neurosci 40(12), 681-690. 
 
Cole, J.H., Leech, R., Sharp, D.J., Alzheimer's Disease Neuroimaging, I., 2015. Prediction of 
brain age suggests accelerated atrophy after traumatic brain injury. Ann Neurol 77(4), 571-581. 
 
Cutuli D. Cognitive reappraisal and expressive suppression strategies role in the emotion 
regulation: an overview on their modulatory effects and neural correlates. Frontiers in systems 
neuroscience. 2014;8:175. 
De Vogelaere, F., Santens, P., Achten, E., Boon, P., Vingerhoets, G., 2010. Hippocampal 
activation during face-name associative memory encoding: blocked versus permuted design. 
Neuroradiology 52(1), 25-36. 
 123 
DeCarli, C., Massaro, J., Harvey, D., Hald, J., Tullberg, M., Au, R., ... & Wolf, P. A. (2005). 
Measures of brain morphology and infarction in the framingham heart study: establishing what is 
normal. Neurobiology of aging, 26(4), 491-510. 
DeCarli, C., Massaro, J., Harvey, D., Hald, J., Tullberg, M., Au, R., & Wolf, P. A. (2005b). 
Measures of brain morphology and infarction in the framingham heart study: establishing what is 
normal. Neurobiology of Aging, 26(4), 491–510.  
 
DePalma, M. J., Ketchum, J. M., & Saullo, T. R. (2012). Multivariable analyses of the 
relationships between age, gender, and body mass index and the source of chronic low back pain. 
Pain Medicine, 13(4), 498-506. 
 
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF, 3rd. Late-life depression and risk of 
vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-
based cohort studies. Br J Psychiatry 2013; 202(5): 329-35. 
 
Diniz, B.S., et al., Plasma biosignature and brain pathology related to persistent cognitive 
impairment in late-life depression. Molecular psychiatry, 2015. 20(5): p. 594. 
 
Dixon, A. N., & Gatchel, R. J. (1999). Gender and parental status as predictors of chronic low 
back pain disability: a prospective study. Journal of Occupational Rehabilitation, 9(3), 195-200. 
 
Dodd, P.R.; Scott, H.L.; Westphalen, R.I. Excitotoxic mechanisms in the pathogenesis of 
dementia.  Neurochem. Int. 1994, 25, 203–219.  
 
Donovan NJ, Locascio JJ, Marshall GA, et al. Longitudinal Association of Amyloid Beta and 
Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry. 
2018:appiajp201717040442. 
 
Droppa, K., et al., Association between change in brain gray matter volume, cognition, and 
depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression. J 
Psychiatr Res, 2017. 95: p. 129-134. 
 
Dumas, J. A. (2015). What is normal cognitive aging? Evidence from task-based functional 
neuroimaging. Current behavioral neuroscience reports, 2(4), 256-261. 
 
Edelman, K., Tudorascu, D., Agudelo, C., Snitz, B., Karim, H., Cohen, A., Mathis, C., Price, J., 
Weissfeld, L., Klunk, W., Aizenstein, H., 2017. Amyloid-Beta Deposition is Associated with 
Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively 
Normal Elderly. Am J Geriatr Psychiatry 25(5), 551-560.  
 
Ehring T, & Watkins, E.R. Repetitive negative thinking as a transdiagnostic process. 
International Journal of Cognitive Therapy. 2008;1(3):192-205. 
Erk, S., Spottke, A., Meisen, A., Wagner, M., Walter, H., Jessen, F., 2011. Evidence of neuronal 
compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry 
68(8), 845-852. 
 124 
Evans, D.A., Hebert, L.E., Beckett, L.A., Scherr, P.A., Albert, M.S., Chown, M.J., Pilgrim, 
D.M., Taylor, J.O., 1997. Education and other measures of socioeconomic status and risk of 
incident Alzheimer disease in a defined population of older persons. Arch Neurol 54(11), 1399-
1405.  
Finch, C. E., & Ruvkun, G. (2001). The genetics of aging. Annual review of genomics and 
human genetics, 2(1), 435-462. 
 
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., Walhovd, K. B., & Alzheimer's Disease 
Neuroimaging Initiative. (2014). What is normal in normal aging? Effects of aging, amyloid and 
Alzheimer's disease on the cerebral cortex and the hippocampus. Progress in neurobiology, 117, 
20-40. 
 
Flor, H., C. Braun, T. Elbert, and N.J.N.l. Birbaumer, Extensive reorganization of primary 
somatosensory cortex in chronic back pain patients. 1997. 224(1): p. 5-8. 
 
Flor, H., C. Denke, M. Schaefer, and S.J.T.L. Grüsser, Effect of sensory discrimination training 
on cortical reorganisation and phantom limb pain. 2001. 357(9270): p. 1763-1764. 
 
Foster, N.E., J.R. Anema, D. Cherkin, R. Chou, S.P. Cohen, et al., Prevention and treatment of 
low back pain: evidence, challenges, and promising directions. The Lancet, 2018. 391(10137): p. 
2368-2383. 
 
Fotenos, A. F., Snyder, A. Z., Girton, L. E., Morris, J. C., & Buckner, R. L. (2005). Normative 
estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology, 
64(6), 1032-1039. 
 
Franklin, T.B., B.J. Saab, and I.M. Mansuy, Neural mechanisms of stress resilience and 
vulnerability. Neuron, 2012. 75(5): p. 747-761.  
 
Frodl, T. and V. O'Keane, How does the brain deal with cumulative stress? A review with focus 
on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiology 
of disease, 2013. 52: p. 24-37. 
Garcia-Ptacek, S., Eriksdotter, M., Jelic, V., Porta-Etessam, J., Kareholt, I., Manzano Palomo, S., 
2016. Subjective cognitive impairment: Towards early identification of Alzheimer disease. 
Neurologia 31(8), 562-571.  
Gaser, C., Franke, K., Kloppel, S., Koutsouleris, N., Sauer, H., Alzheimer's Disease 
Neuroimaging, I., 2013. BrainAGE in Mild Cognitive Impaired Patients: Predicting the 
Conversion to Alzheimer's Disease. PLoS One 8(6), e67346. 
 
Gerhart, J.I., J.W. Burns, S. Bruehl, D.A. Smith, K.M. Post, et al., Variability in negative 
emotions among individuals with chronic low back pain: relationships with pain and function. 
Pain, 2018. 159(2): p. 342-350. 
 125 
Gilewski, M.J., Zelinski, E.M., Schaie, K.W., 1990. The Memory Functioning Questionnaire for 
assessment of memory complaints in adulthood and old age. Psychol Aging 5(4), 482-490. 
Giuliani NR, Drabant EM, Bhatnagar R, Gross JJ. Emotion regulation and brain plasticity: 
expressive suppression use predicts anterior insula volume. Neuroimage. 2011;58(1):10-15. 
 
Giuliani NR, Drabant EM, Gross JJ. Anterior cingulate cortex volume and emotion regulation: is 
bigger better? Biological psychology. 2011;86(3):379-382. 
 
Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the 
MIRAGE Study. Arch Neurol 2003; 60(5): 753-9. 
 
Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for 
affect, relationships, and well-being. J Pers Soc Psychol. 2003;85(2):348-362. 
 
Gross JJ. Antecedent- and response-focused emotion regulation: divergent consequences for 
experience, expression, and physiology. J Pers Soc Psychol. 1998;74(1):224-237. 
 
Gunning, F.M., et al., Anterior cingulate cortical volumes and treatment remission of geriatric 
depression. International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life 
and allied sciences, 2009. 24(8): p. 829-836. 
 
Gustavson DE, du Pont A, Whisman MA, Miyake A. Evidence for Transdiagnostic Repetitive 
Negative Thinking and Its Association with Rumination, Worry, and Depression and Anxiety 
Symptoms: A Commonality Analysis. Collabra Psychol. 2018;4(1). 
 
Han, S.D., Bangen, K.J., Bondi, M.W., 2009. Functional magnetic resonance imaging of 
compensatory neural recruitment in aging and risk for Alzheimer's disease: review and 
recommendations. Dement Geriatr Cogn Disord 27(1), 1-10.  
 
Hanley AW, Garland EL. Dispositional Mindfulness Co-varies with Self-Reported Positive 
Reappraisal. Pers Individ Dif. 2014;66:146-152. 
 
Hartvigsen, J., M.J. Hancock, A. Kongsted, Q. Louw, M.L. Ferreira, et al., What low back pain 
is and why we need to pay attention. The Lancet, 2018. 391(10137): p. 2356-2367. 
 
Hayes JP, Morey RA, Petty CM, et al. Staying cool when things get hot: emotion regulation 
modulates neural mechanisms of memory encoding. Frontiers in human neuroscience. 
2010;4:230. 
Hayes, J.M., Tang, L., Viviano, R.P., van Rooden, S., Ofen, N., Damoiseaux, J.S., 2017. 
Subjective memory complaints are associated with brain activation supporting successful 
memory encoding. Neurobiol Aging 60, 71-80. 
Hermann A, Bieber A, Keck T, Vaitl D, Stark R. Brain structural basis of cognitive reappraisal 
and expressive suppression. Soc Cogn Affect Neurosci. 2014;9(9):1435-1442. 
 126 
 
Hsieh, M.H., et al., Hippocampal volume and antidepressant response in geriatric depression. 
International journal of geriatric psychiatry, 2002. 17(6): p. 519-525. 
Hung, C.I., C.Y. Liu, and T.S. Fu, Depression: An important factor associated with disability 
among patients with chronic low back pain. Int J Psychiatry Med, 2015. 49(3): p. 187-98. 
 
Ivo, R., A. Nicklas, J. Dargel, R. Sobottke, K.S. Delank, P. Eysel, and B. Weber, Brain structural 
and psychometric alterations in chronic low back pain. Eur Spine J, 2013. 22(9): p. 1958-64. 
 
Jack, C.R., Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, 
L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C., 
Trojanowski, J.Q., 2013. Tracking pathophysiological processes in Alzheimer's disease: an 
updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2), 207-216. 
 
Janssen, J., et al., Cerebral volume measurements and subcortical white matter lesions and short‐
term treatment response in late life depression. International Journal of Geriatric Psychiatry: A 
journal of the psychiatry of late life and allied sciences, 2007. 22(5): p. 468-474. 
 
Jessen, F., Amariglio, R.E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chetelat, G., Dubois, B., 
Dufouil, C., Ellis, K.A., van der Flier, W.M., Glodzik, L., van Harten, A.C., de Leon, M.J., 
McHugh, P., Mielke, M.M., Molinuevo, J.L., Mosconi, L., Osorio, R.S., Perrotin, A., Petersen,  
Jin, J., Maren, S., 2015. Prefrontal-Hippocampal Interactions in Memory and Emotion. Front 
Syst Neurosci 9, 170. 
Joshi, S.H., et al., Structural plasticity of the hippocampus and amygdala induced by 
electroconvulsive therapy in major depression. Biological psychiatry, 2016. 79(4): p. 282-292. 
 
Just N, Alloy LB. The response styles theory of depression: tests and an extension of the theory. 
J Abnorm Psychol. 1997;106(2):221-229. 
 
Karim H, Tudorascu DL, Aizenstein H, Walker S, Good R, Andreescu C. Emotion Reactivity 
and Cerebrovascular Burden in Late-Life GAD: A Neuroimaging Study. Am J Geriatr 
Psychiatry. 2016;24(11):1040-1050. 
 
Karim HT, Andreescu C, MacCloud RL, et al. The effects of white matter disease on the 
accuracy of automated segmentation. Psychiatry Research: Neuroimaging. 2016;253:7-14. 
 
Karim HT, Tudorascu DL, Butters MA, Walker S, Aizenstein HJ, Andreescu C. In the grip of 
worry: cerebral blood flow changes during worry induction and reappraisal in late-life 
generalized anxiety disorder. Translational psychiatry. 2017;7(8):e1204. 
 
Karim, H.T., et al., Acute trajectories of neural activation predict remission to pharmacotherapy 
in late-life depression. Neuroimage Clin, 2018. 19: p. 831-839. 
 
 127 
Karim, H.T., et al., Intrinsic functional connectivity in late-life depression: trajectories over the 
course of pharmacotherapy in remitters and non-remitters. Mol Psychiatry, 2017. 22(3): p. 450-
457. 
Karim, H.T., et al., The effects of white matter disease on the accuracy of automated 
segmentation. Psychiatry Research: Neuroimaging, 2016. 253: p. 7-14. 
 
Karp, A., Kareholt, I., Qiu, C., Bellander, T., Winblad, B., Fratiglioni, L., 2004. Relation of 
education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J 
Epidemiol 159(2), 175-183.  
 
Karp, J.F., B.L. Rollman, C.F. Reynolds III, J.Q. Morse, F. Lotrich, et al., Addressing both 
depression and pain in late life: the methodology of the ADAPT study. 2012. 13(3): p. 405-418. 
 
Kessler R, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of 
DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 
2005;62(6):593–602.  
 
Khalaf, A., et al., Altered Functional Magnetic Resonance Imaging Markers of Affective 
Processing During Treatment of Late-Life Depression. Am J Geriatr Psychiatry, 2016. 24(10): p. 
791-801. 
Kliegel, M., Zimprich, D., Eschen, A., 2005. What do subjective cognitive complaints in persons 
with aging-associated cognitive decline reflect? Int Psychogeriatr 17(3), 499-512. 
Knight, R.G., McMahon, J., Green, T.J., Skeaff, C.M., 2004. Some Normative and Psychometric 
Data for the Geriatric Depression Scale and the Cognitive Failures Questionnaire from a Sample 
of Healthy Older Persons. New Zealand Journal of Psychology 33(3).  
Koen, J. D., & Rugg, M. D. (2019). Neural dedifferentiation in the aging brain. Trends in 
cognitive sciences. 
 
Kregel, J., M. Meeus, A. Malfliet, M. Dolphens, L. Danneels, J. Nijs, and B. Cagnie, Structural 
and functional brain abnormalities in chronic low back pain: A systematic review. Semin 
Arthritis Rheum, 2015. 45(2): p. 229-37. 
 
Kumar, A., et al., Atrophy and high intensity lesions: complementary neurobiological 
mechanisms in late-life major depression. Neuropsychopharmacology, 2000. 22(3): p. 264-274. 
 
Lambiase MJ, Kubzansky LD, Thurston RC. Prospective study of anxiety and incident stroke. 
Stroke. 2014;45(2):438-443. 
 
Lenze EJ, Mulsant BH, Shear MK, Schulberg HC, Dew MA, Begley AE, et al. Comorbid 
anxiety disorders in depressed elderly patients. Am J Psychiatry. 2000;157(5):722–8.  
 
Lenze, E.J., et al., Incomplete response in late-life depression: getting to remission. Dialogues in 
clinical neuroscience, 2008. 10(4): p. 419. 
 128 
 
Li, Q.; Wang, S.; Milot, E.; Bergeron, P.; Ferrucci, L.; Fried, L.P.; Cohen, A.A. Homeostatic 
dysregulation proceeds in parallel in multiple physiological systems. Aging Cell 2015, 14, 1103–
1112  
 
Liem, F., Varoquaux, G., Kynast, J., Beyer, F., Kharabian Masouleh, S., Huntenburg, J.M., 
Lampe, L., Rahim, M., Abraham, A., Craddock, R.C., Riedel-Heller, S., Luck, T., Loeffler, M., 
Schroeter, M.L., Witte, A.V., Villringer, A., Margulies, D.S., 2017. Predicting brain-age from 
multimodal imaging data captures cognitive impairment. Neuroimage 148, 179-188. 
 
Livingstone KM, Isaacowitz DM. The roles of age and attention in general emotion regulation, 
reappraisal, and expressive suppression. Psychol Aging. 2018;33(3):373-383. 
 
Lockhart, S. N., & DeCarli, C. (2014). Structural imaging measures of brain aging. 
Neuropsychology review, 24(3), 271-289. 
 
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks 
of aging. Cell, 153(6), 1194-1217. 
Lopresti, B.J., Klunk, W.E., Mathis, C.A., Hoge, J.A., Ziolko, S.K., Lu, X., Meltzer, C.C., 
Schimmel, K., Tsopelas, N.D., DeKosky, S.T., Price, J.C., 2005. Simplified quantification of 
Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 
46(12), 1959-1972.  
Ly M, Andreescu C. Advances and Barriers for Clinical Neuroimaging in Late-Life Mood and 
Anxiety Disorders. Curr Psychiatry Rep 2018; 20(1): 7. 
 
Ly M, Yu GZ, Karim HT, et al. Improving brain age prediction models: incorporation of 
amyloid status in Alzheimer's disease. Neurobiol Aging. 2019. 
 
MacKay DJ, Mac Kay DJ. Information theory, inference and learning algorithms. Cambridge 
university press; 2003. 
 
Mackin, R.S., et al., Patterns of reduced cortical thickness in late-life depression and relationship 
to psychotherapeutic response. The American Journal of Geriatric Psychiatry, 2013. 21(8): p. 
794-802. 
Manly, J.J., Schupf, N., Tang, M.X., Stern, Y., 2005. Cognitive decline and literacy among 
ethnically diverse elders. J Geriatr Psychiatry Neurol 18(4), 213-217. 
Marano, C.M., et al., Structural imaging in late-life depression: association with mood and 
cognitive responses to antidepressant treatment. The American Journal of Geriatric Psychiatry, 
2015. 23(1): p. 4-12. 
 
Marchant NL, Howard RJ. Cognitive debt and Alzheimer's disease. J Alzheimers Dis. 
2015;44(3):755-770. 
 129 
McCrae, R.R., Costa, J., Paul T, 2007. Brief versions of the NEO-PI-3. Journal of individual 
differences 28(3), 116-128.  
McEvoy PM, Watson H, Watkins ER, Nathan P. The relationship between worry, rumination, 
and comorbidity: evidence for repetitive negative thinking as a transdiagnostic construct. J 
Affect Disord. 2013;151(1):313-320. 
McKinney, B.C. and E. Sibille, The age-by-disease interaction hypothesis of late-life depression. 
The American Journal of Geriatric Psychiatry, 2013. 21(5): p. 418-432. 
 
Meier‐Ruge WI, Ulrich J, Brühlmann M, Meier E. Age‐related white matter atrophy in the 
human brain. Annals of the New York Academy of Sciences. 1992 Dec;673(1):260-9. 
Menon, V., 2015. Salience network, In: Arthur W. Toga, editor. Brain Mapping: An 
Encyclopedic Reference. Academic Press: Elsevier, pp. 597-611. 
Merino, J. G. (2019, March). White Matter Hyperintensities on Magnetic Resonance Imaging: 
What Is a Clinician to Do?. In Mayo Clinic Proceedings (Vol. 94, No. 3, pp. 380-382). Elsevier. 
 
Meucci, R.D., A.G. Fassa, and N.M. Faria, Prevalence of chronic low back pain: systematic 
review. Rev Saude Publica, 2015. 49. 
 
Mizuno, A., Ly, M., Aizenstein, H.J., 2018. A Homeostatic Model of Subjective Cognitive 
Decline. Brain Sci 8(12).  
 
Moons KG, Donders RA, Stijnen T, Harrell FE, Jr. Using the outcome for imputation of missing 
predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092-1101. 
 
Morimoto SS, Kanellopoulos D, Manning KJ, Alexopoulos GS. Diagnosis and treatment of 
depression and cognitive impairment in late life. Ann N Y Acad Sci 2015; 1345: 36-46. 
 
Munce, S. E., & Stewart, D. E. (2007). Gender differences in depression and chronic pain 
conditions in a national epidemiologic survey. Psychosomatics, 48(5), 394-399. 
 
Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research--part 2: multiple 
imputation. Acad Emerg Med. 2007;14(7):669-678. 
Niendam, T.A., Laird, A.R., Ray, K.L., Dean, Y.M., Glahn, D.C., Carter, C.S., 2012. Meta- 
analytic evidence for a superordinate cognitive control network subserving diverse executive 
functions. Cogn Affect Behav Neurosci 12(2), 241-268. 
Nolen-Hoeksema S. The role of rumination in depressive disorders and mixed anxiety/depressive 
symptoms. J Abnorm Psychol. 2000;109(3):504-511. 
 
O'Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: 




O'Donovan A, Slavich GM, Epel ES, Neylan TC. Exaggerated neurobiological sensitivity to 
threat as a mechanism linking anxiety with increased risk for diseases of aging. Neurosci 
Biobehav Rev. 2013;37(1):96-108. 
Okereke OI, Grodstein F. Phobic anxiety and cognitive performance over 4 years among 
community-dwelling older women in the Nurses' Health Study. Am J Geriatr Psychiatry. 
2013;21(11):1125-1134. 
 
Okereke OI, Prescott J, Wong JY, Han J, Rexrode KM, De Vivo I. High phobic anxiety is related 
to lower leukocyte telomere length in women. PLoS One. 2012;7(7):e40516. 
 
Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O., Yu, 
G.Q., Kreitzer, A., Finkbeiner, S., Noebels, J.L., Mucke, L., 2007. Aberrant excitatory neuronal 
activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of 
Alzheimer's disease. Neuron 55(5), 697-711.  
 
Pardoe, H.R., et al., Structural brain changes in medically refractory focal epilepsy resemble 
premature brain aging. Epilepsy research, 2017. 133: p. 28-32. 
 
Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. Statistical parametric mapping: the 
analysis of functional brain images. Elsevier; 2011. 
 
Perna G, Iannone G, Alciati A, Caldirola D. Are Anxiety Disorders Associated with Accelerated 
Aging? A Focus on Neuroprogression. Neural Plast. 2016;2016:8457612. 
Perrotin, A., Mormino, E.C., Madison, C.M., Hayenga, A.O., Jagust, W.J., 2012. Subjective 
cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission 
tomography study in normal elderly individuals. Arch Neurol 69(2), 223-229. 
Pfefferbaum, A., Rohlfing, T., Rosenbloom, M. J., Chu, W., Colrain, I. M., & Sullivan, E. V. 
(2013). Variation in longitudinal trajectories of regional brain volumes of healthy men and 
women (ages 10 to 85 years) measured with atlas-based parcellation of MRI. Neuroimage, 65, 
176-193. 
 
Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid-beta, anxiety, and cognitive decline in 
preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA psychiatry. 
2015;72(3):284-291. 
 
Pietrzak RH, Maruff P, Woodward M, et al. Mild worry symptoms predict decline in learning 
and memory in healthy older adults: a 2-year prospective cohort study. Am J Geriatr Psychiatry. 
2012;20(3):266-275. 
 
Pietrzak RH, Scott JC, Neumeister A, et al. Anxiety symptoms, cerebral amyloid burden and 
memory decline in healthy older adults without dementia: 3-year prospective cohort study. Br J 
Psychiatry. 2014;204:400-401. 
 131 
Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer, 
C.C., DeKosky, S.T., Mathis, C.A., 2005. Kinetic modeling of amyloid binding in humans using 
PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25(11), 1528-1547.  
R.C., Rabin, L.A., Rami, L., Reisberg, B., Rentz, D.M., Sachdev, P.S., de la Sayette, V., Saykin, 
A.J., Scheltens, P., Shulman, M.B., Slavin, M.J., Sperling, R.A., Stewart, R., Uspenskaya, O., 
Vellas, B., Visser, P.J., Wagner, M., Subjective Cognitive Decline Initiative Working, G., 2014. 
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's 
disease. Alzheimers Dement 10(6), 844-852.  
Reisberg, B., Shulman, M.B., Torossian, C., Leng, L., Zhu, W., 2010. Outcome over seven years 
of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 6(1), 
11-24.  
Revest JM, Dupret D, Koehl M, et al. Adult hippocampal neurogenesis is involved in anxiety-
related behaviors. Mol Psychiatry. 2009;14(10):959-967. 
 
Reynolds K, Pietrzak RH, El-Gabalawy R, et al. Prevalence of psychiatric disorders in US older 
adults: findings from a nationally representative survey. World Psychiatr 2015;14:74–81.  
 
Ribeiz, S.R., et al., Structural brain changes as biomarkers and outcome predictors in patients 
with late-life depression: a cross-sectional and prospective study. PloS one, 2013. 8(11): p. 
e80049. 
 
Riddle M, Potter GG, McQuoid DR, Steffens DC, Beyer JL, Taylor WD. Longitudinal Cognitive 
Outcomes of Clinical Phenotypes of Late-Life Depression. Am J Geriatr Psychiatry 2017; 
25(10): 1123-34. 
Rodda, J.E., Dannhauser, T.M., Cutinha, D.J., Shergill, S.S., Walker, Z., 2009. Subjective 
cognitive impairment: increased prefrontal cortex activation compared to controls during an 
encoding task. Int J Geriatr Psychiatry 24(8), 865-874. 
Rosario, B.L., Weissfeld, L.A., Laymon, C.M., Mathis, C.A., Klunk, W.E., Berginc, M.D., 
James, J.A., Hoge, J.A., Price, J.C., 2011. Inter-rater reliability of manual and automated region- 
of-interest delineation for PiB PET. Neuroimage 55(3), 933-941.  
Sacuiu, S., et al., Chronic depressive symptomatology in mild cognitive impairment is associated 
with frontal atrophy rate which hastens conversion to Alzheimer dementia. The American 
Journal of Geriatric Psychiatry, 2016. 24(2): p. 126-135. 
 
Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence 
of Alzheimer's disease. Neurology. 2001;57(12):2236-42. 
 
Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3-15. 
 132 
Schmidt-Wilcke, T., E. Leinisch, S. Ganssbauer, B. Draganski, U. Bogdahn, J. Altmeppen, and 
A. May, Affective components and intensity of pain correlate with structural differences in gray 
matter in chronic back pain patients. Pain, 2006. 125(1-2): p. 89-97. 
 
Schnack, H.G., et al., Accelerated brain aging in schizophrenia: a longitudinal pattern 
recognition study. American Journal of Psychiatry, 2016. 173(6): p. 607-616. 
 
Schrouff, J., Rosa, M.J., Rondina, J.M., Marquand, A.F., Chu, C., Ashburner, J., Phillips, C., 
Richiardi, J., Mourao-Miranda, J., 2013. PRoNTo: pattern recognition for neuroimaging toolbox. 
Neuroinformatics 11(3), 319-337. 
Schultz, W., Tremblay, L., Hollerman, J.R., 2000. Reward processing in primate orbitofrontal 
cortex and basal ganglia. Cereb Cortex 10(3), 272-284. 
Segerstrom SC, Roach AR, Evans DR, Schipper LJ, Darville AK. The structure and health 
correlates of trait repetitive thought in older adults. Psychol Aging. 2010;25(3):505-515. 
Seignourel P, Kunik M, Snow L, et al. Anxiety in dementia: a critical review. Clin Psychol Rev 
2008;28(7):1071–82.   
Sharp, E.S., Gatz, M., 2011. Relationship between education and dementia: an updated 
systematic review. Alzheimer Dis Assoc Disord 25(4), 289-304.  
Simpson, S.W., et al., Regional cerebral volume measurements in late‐life depression: 
relationship to clinical correlates, neuropsychological impairment and response to treatment. 
International journal of geriatric psychiatry, 2001. 16(5): p. 469-476. 
Sivertsen, H., et al., Depression and quality of life in older persons: a review. Dementia and 
Geriatric Cognitive Disorders, 2015. 40(5-6): p. 311-339. 
Slot, R.E.R., Verfaillie, S.C.J., Overbeek, J.M., Timmers, T., Wesselman, L.M.P., Teunissen, 
C.E., Dols, A., Bouwman, F.H., Prins, N.D., Barkhof, F., Lammertsma, A.A., Van Berckel, 
B.N.M., Scheltens, P., Sikkes, S.A.M., Van der Flier, W.M., 2018. Subjective Cognitive 
Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther 10(1), 76.  
Snitz, B.E., Lopez, O.L., McDade, E., Becker, J.T., Cohen, A.D., Price, J.C., Mathis, C.A., 
Klunk, W.E., 2015a. Amyloid-beta Imaging in Older Adults Presenting to a Memory Clinic with 
Subjective Cognitive Decline: A Pilot Study. J Alzheimers Dis 48 Suppl 1, S151-159.  
Snitz, B.E., Weissfeld, L.A., Cohen, A.D., Lopez, O.L., Nebes, R.D., Aizenstein, H.J., McDade, 
E., Price, J.C., Mathis, C.A., Klunk, W.E., 2015b. Subjective Cognitive Complaints, Personality 
and Brain Amyloid-beta in Cognitively Normal Older Adults. Am J Geriatr Psychiatry 23(9), 
985-993.  
Snitz, B.E., Yu, L., Crane, P.K., Chang, C.C., Hughes, T.F., Ganguli, M., 2012. Subjective 
cognitive complaints of older adults at the population level: an item response theory analysis. 
Alzheimer Dis Assoc Disord 26(4), 344-351. 
 133 
Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., 
Jack, C.R., Jr., Kaye, J., Montine, T.J., Park, D.C., Reiman, E.M., Rowe, C.C., Siemers, E., 
Stern, Y., Yaffe, K., Carrillo, M.C., Thies, B., Morrison-Bogorad, M., Wagster, M.V., Phelps, 
C.H., 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations 
from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic 
guidelines for Alzheimer's disease. Alzheimers Dement 7(3), 280-292. 
Sperling, R.A., Laviolette, P.S., O'Keefe, K., O'Brien, J., Rentz, D.M., Pihlajamaki, M., 
Marshall, G., Hyman, B.T., Selkoe, D.J., Hedden, T., Buckner, R.L., Becker, J.A., Johnson, 
K.A., 2009. Amyloid deposition is associated with impaired default network function in older 
persons  
Stern Y, Arenaza-Urquijo EM, Bartres-Faz D, et al. Whitepaper: Defining and investigating 
cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement 2018. 
 
Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11(11): 
1006-12. 
Stern, Y., 2009. Cognitive reserve. Neuropsychologia 47(10), 2015-2028. 
Stern, Y., 2012. Cognitive reserve in ageing and Alzheimer's disease. The Lancet Neurology 
11(11), 1006-1012. 
Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms 
linking vascular disease with depression. Mol Psychiatry 2013; 18(9): 963-74. 
Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and 
meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity 
risk in coronary heart disease. J Psychosom Res. 2014;77(6):439-448. 
 
Tully PJ, Cosh SM, Baune BT. A review of the affects of worry and generalized anxiety disorder 
upon cardiovascular health and coronary heart disease. Psychology, health & medicine. 
2013;18(6):627-644. 
Ullsperger, M., Danielmeier, C., Jocham, G., 2014. Neurophysiology of performance monitoring 
and adaptive behavior. Physiol Rev 94(1), 35-79. 
Urry HL, Gross, JJ. Emotion Regulation in Older Age. Current Dirrections inPsychological 
Science. 2010;19 (6): 352-357. 
 
Valiengo Lda C, Stella F, Forlenza OV. Mood disorders in the elderly: prevalence, functional 
impact, and management challenges. Neuropsychiatr Dis Treat 2016; 12: 2105-14. 
 
van Oijen, M., de Jong, F.J., Hofman, A., Koudstaal, P.J., Breteler, M.M., 2007. Subjective 
memory complaints, education, and risk of Alzheimer's disease. Alzheimers Dement 3(2), 92-97.  
 134 
Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, et al. 
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of 
cognition. Brain. 2011;134(Pt 5):1479-92. 
 
Vernooij, M. W., de Groot, M., van der Lugt, A., Ikram, M. A., Krestin, G. P., Hofman, A., ... & 
Breteler, M. M. (2008). White matter atrophy and lesion formation explain the loss of structural 
integrity of white matter in aging. Neuroimage, 43(3), 470-477. 
Vogel, J.W., Varga Dolezalova, M., La Joie, R., Marks, S.M., Schwimmer, H.D., Landau, S.M., 
Jagust, W.J., 2017. Subjective cognitive decline and beta-amyloid burden predict cognitive 
change in healthy elderly. Neurology 89(19), 2002-2009. 
Wand, B.M., L. Parkitny, N.E. O'Connell, H. Luomajoki, J.H. McAuley, M. Thacker, and G.L. 
Moseley, Cortical changes in chronic low back pain: current state of the art and implications for 
clinical practice. Man Ther, 2011. 16(1): p. 15-20. 
 
Wang HX, MacDonald SW, Dekhtyar S, Fratiglioni L. Association of lifelong exposure to 
cognitive reserve-enhancing factors with dementia risk: A community-based cohort study. PLoS 
Med. 2017;14(3): e1002251. 
 
Wilson, R. S., Beckett, L. A., Bennett, D. A., Albert, M. S., & Evans, D. A. (1999). Change in 
cognitive function in older persons from a community population: relation to age and Alzheimer 
disease. Archives of Neurology, 56(10), 1274–1279. 
 
Zhang X, Norton J, Carriere I, Ritchie K, Chaudieu I, Ancelin ML. Generalized anxiety in 
community-dwelling elderly: prevalence and clinical characteristics. J Affect Disord. 
2015;172:24–9.  
 
 
